var title_f18_61_19408="GAVE endosc";
var content_f18_61_19408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric antral vascular ectasia (watermelon stomach)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy in a patient with gastric antral vascular ectasia (GAVE) shows the antrum and the pylorus (center) with erythematous radial stripes resembling the rind of a watermelon. The patient presented with iron deficiency anemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Bailen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19408=[""].join("\n");
var outline_f18_61_19408=null;
var title_f18_61_19409="Direct indirect allorecognition";
var content_f18_61_19409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Schematic representation showing direct and indirect allorecognition during graft rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T cell recognition of alloantigen occurs by one of two separate pathways. T cell activation by the \"direct\" pathway occurs when T cells encounter intact donor MHC on the surface of donor antigen-presenting cells (APC). This pathway is thought to be of dominant importance during early acute rejection as engrafted organs contain a large number of passenger leukocytes. Intact donor MHC molecules are also known to be continuously shed into the circulation where they may then be endocytosed by the recipient's antigen-presenting cells. Within the acidic endosomal compartment, the MHC proteins are fragmented into their constituent peptides. They are then transferred into the endoplasmic reticulum, loaded into the antigen binding cleft of MHC class II of the recipient and finally expressed on the cell surface of recipients APCs. This mechanism has been referred to as the \"indirect allorecognition.\" However, this is of course the normal route by which T cells normally encounter antigen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19409=[""].join("\n");
var outline_f18_61_19409=null;
var title_f18_61_19410="Circinate balanitis in reactive arthritis";
var content_f18_61_19410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circinate balanitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shallow erythematous erosions in a circinate distribution are present on the glans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Callen, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19410=[""].join("\n");
var outline_f18_61_19410=null;
var title_f18_61_19411="Agar colonies P marneffei";
var content_f18_61_19411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonies of",
"    <em>",
"     Penicillium marneffei",
"    </em>",
"    mycelia after incubating at 25&deg;C on Sabouraud dextrose agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Khuanchai Supparatpinyo and Thira Sirisanthana.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19411=[""].join("\n");
var outline_f18_61_19411=null;
var title_f18_61_19412="Small bowel leiomyosarc Light";
var content_f18_61_19412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Small intestinal leiomyosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low (left panel) and high power (right panel) images of a small bowel leiomyosarcoma. The high power view reveals pleiomorphic spindle cells with nuclear atypia, hypercellularity, and several mitotic figures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Saint Aufranc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19412=[""].join("\n");
var outline_f18_61_19412=null;
var title_f18_61_19413="Zidovudine and lamivudine: Pediatric drug information";
var content_f18_61_19413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zidovudine and lamivudine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"    see \"Zidovudine and lamivudine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/1/32789?source=see_link\">",
"    see \"Zidovudine and lamivudine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Combivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Combivir&reg;;",
"     </li>",
"     <li>",
"      Teva-Lamivudine/Zidovudine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"      see \"Zidovudine and lamivudine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with at least one other antiretroviral agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV Treatment:",
"     </b>",
"     Children &ge;30 kg, Adolescents &ge;30 kg, and Adults: Oral: One tablet twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use not recommended; use individual agents for reduction in lamivudine and zidovudine dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use not recommended; use individual antiretroviral agents to reduce dosage.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral: Lamivudine 150 mg and zidovudine 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Combivir&reg;: Lamivudine 150 mg and zidovudine 300 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F16351407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with at least one other antiretroviral agent (FDA approved in children &ge;30 kg, adolescents &ge;30 kg, and adults).",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F235261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Combivir&reg; may be confused with Combivent&reg;, Epivir&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AZT is an error-prone abbreviation (mistaken as azaTHIOprine, aztreonam)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lamivudine, zidovudine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Always use lamivudine and zidovudine in combination with another antiretroviral agent. Use with extreme caution and only if there is no satisfactory alternative therapy in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Use with caution in patients with bone marrow compromise or in patients with impaired renal or hepatic function. The dose of lamivudine should be reduced in patients with renal dysfunction; the dose of zidovudine should be reduced or therapy interrupted in patients with anemia, granulocytopenia, myopathy, renal or hepatic impairment, or liver cirrhosis. Use of the fixed-dose combination product is",
"     <b>",
"      not",
"     </b>",
"     recommended for patients who need a dosage reduction, including children &lt;30 kg, patients with renal or hepatic impairment, or those patients experiencing dose-limiting adverse effects (use individual antiretroviral agents to appropriately adjust dosages).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Combivir&reg; contains lamivudine and zidovudine as a fixed-dose combination.  Do not administer Combivir&reg; with other lamivudine or zidovudine containing medications (eg.Epivir&reg;, Epzicom&reg;, Retrovir&reg;, Trizivir&reg;) or with medications that contain emtricitabine (e.g. Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, Truvada&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . In HIV-infected patients who are coinfected with hepatitis B, severe acute exacerbations of HBV have occurred after discontinuation of lamivudine containing medications",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; follow hepatic function of HBV-infected patients closely (clinically and with laboratory tests) for at least several months after discontinuing lamivudine therapy; initiate antihepatitis B therapy if needed. Testing for HBV is recommended prior to the initiation of lamivudine and zidovudine therapy; treatment of HIV in patients with unrecognized/untreated HBV may lead to rapid HBV resistance. Concomitant use of combination antiretroviral therapy with interferon alfa (with or without ribavirin) has resulted in hepatic decompensation (with some fatalities) in patients coinfected with HIV and HCV; monitor patients closely, especially for hepatic decompensation, neutropenia, and anemia; consider discontinuation of lamivudine and zidovudine if needed; consider dose reduction or discontinuation of interferon alfa, ribavirin, or both if clinical toxicities, including hepatic decompensation, worsen. Concomitant use of ribavirin and zidovudine may also result in exacerbation of anemia (concurrent use is",
"     <b>",
"      not",
"     </b>",
"     recommended).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Zidovudine is associated with hematologic toxicity including granulocytopenia and severe anemia requiring transfusions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients with ANC &lt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or hemoglobin &lt;9.5 g/dL; consider interruption of therapy for significant anemia (Hgb &lt;7.5 g/dL or reduction &gt;25% of baseline) or neutropenia (ANC &lt;750 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or reduction &gt;50% from baseline); use of erythropoietin, filgrastim, or reduced zidovudine dosage may be necessary in some patients. Prolonged use of zidovudine may cause myositis and myopathy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Cases of lactic acidosis, severe hepatomegaly with steatosis, and death have been reported with the use of lamivudine, zidovudine and other antiretroviral agents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue therapy in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The major clinical toxicity of lamivudine in pediatric patients is pancreatitis; discontinue therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F235250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons: May enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: May increase the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Zidovudine may enhance the adverse/toxic effect of Ribavirin. Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin.  Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Zidovudine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: Zidovudine may diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note",
"     </b>",
"     : Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load.  Albumin, total protein, calcium, phosphate, lipid panel, and urinalysis every 6-12 months  (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, hepatotoxicity, pancreatitis, anemia, or lactic acidosis.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One Combivir&reg; tablet is bioequivalent to one lamivudine 150 mg tablet plus one zidovudine 300 mg tablet; see individual agents",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/1/32789?source=see_link\">",
"      see \"Zidovudine and lamivudine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; lamivudine and zidovudine is not a cure; notify physician if persistent severe abdominal pain, nausea, or vomiting occurs; take lamivudine and zidovudine every day as prescribed; do not change dose or discontinue without physician's advice. If a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Do not take Combivir&reg; with other lamivudine or zidovudine containing medications (eg, Epivir&reg;, Epzicom&reg;, Retrovir&reg;, Trizivir&reg;) or with medications that contain emtricitabine (eg, Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, Truvada&reg;).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/61/19413/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12540 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19413=[""].join("\n");
var outline_f18_61_19413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708844\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235239\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235240\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056101\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056095\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235227\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235216\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056104\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16351407\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056103\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235261\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235259\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056107\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056094\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056093\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235250\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056109\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235224\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235234\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056100\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056092\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056106\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056099\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12540\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12540|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=related_link\">",
"      Zidovudine and lamivudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/1/32789?source=related_link\">",
"      Zidovudine and lamivudine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_61_19414="Axitinib: Patient drug information";
var content_f18_61_19414=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Axitinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     see \"Axitinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13811819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Inlyta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15125561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Inlyta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13786804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3651282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may only get this drug from certain pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13786805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3644674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat renal cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13786722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3644677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to axitinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13786724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697228",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your urine checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13786821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3001761",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Redness or irritation of the palms of hands or soles of feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Holes in the GI (gastrointestinal) tract may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13786725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to handle heat or cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13786807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3644680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13786723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3644683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up after taking a dose, skip dose and return to normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13786825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13786726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83365 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-849A01EE32-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19414=[""].join("\n");
var outline_f18_61_19414=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13811819\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125561\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786804\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786805\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786722\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786724\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786821\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786725\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786807\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786723\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786825\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13786726\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=related_link\">",
"      Axitinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_61_19415="Treatment and prevention of syphilis in the HIV-infected patient";
var content_f18_61_19415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of syphilis in the HIV-infected patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19415/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19415/contributors\">",
"     Anne Rompalo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19415/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19415/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19415/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19415/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/61/19415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the treatment of syphilis in the HIV-infected patient is generally similar to the HIV-seronegative host, with some important caveats, as discussed below.",
"   </p>",
"   <p>",
"    The treatment, monitoring, and prevention of syphilis in the HIV-infected patient are discussed here. The epidemiology, clinical features, and diagnosis of syphilis in the HIV-infected patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HIV-infected patient with syphilis should be treated with the same regimens as recommended for HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The exact formulation varies with the stage of syphilis, but penicillin is the drug of choice.",
"   </p>",
"   <p>",
"    Although alternative drugs have been utilized for the treatment of syphilis in HIV-seronegative patients, there are very limited data on the efficacy of these medications in the HIV-infected patient [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Primary and secondary syphilis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are conflicting data as to whether HIV status has an impact on treatment outcomes or serologic responses. Several studies have suggested that serologically-defined treatment failures may be more common among HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The clinical import of this laboratory finding is unclear since this may be the result of slower declines in non-treponemal serologies rather than a lack of clinical response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, in one prospective, multicenter, randomized trial of 541 patients, of whom 19 percent of whom were HIV-seropositive, no difference in clinical outcomes (resolution of rash or ulcers) was seen at one-year follow-up, regardless of HIV status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29143887\">",
"    <span class=\"h2\">",
"     Impact of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest that HIV-infected persons taking potent antiretroviral therapy (ART) may have better overall treatment responses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 231 patients with syphilis, use of any highly active antiretroviral therapy before diagnosis reduced the odds of neurosyphilis by 65 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study of 112 patients with clinical or serologic evidence of syphilis, patients taking antiretroviral therapy were almost four times more likely to have normalization of cerebrospinal fluid WBC and protein levels and were 13 times more likely to have resolution of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retrospective data suggest that immunologic recovery with ART is associated with lower rates of serologic failure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment recommendations follow below for HIV-infected patients; however, it should be noted that most of these guidelines are mainly based on data in HIV-seronegative patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary and secondary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended treatment for primary and secondary syphilis is long-acting benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2.4 million units IM) in a single dose&nbsp;(",
"    <a class=\"graphic graphic_algorithm graphicRef79954 \" href=\"UTD.htm?36/18/37152\">",
"     algorithm 1",
"    </a>",
"    ). A clinical trial which compared standard benzathine penicillin versus benzathine penicillin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    did not enhance clinical efficacy among patients with early syphilis, regardless of HIV status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with neurosyphilis or syphilitic ocular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/15\">",
"     15",
"    </a>",
"    ] should be treated with aqueous crystalline",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (3 to 4 million units IV every four hours or as a continuous infusion for a total daily dose of 18 to 24 million units) for 10 to 14 days (",
"    <a class=\"graphic graphic_table graphicRef86764 \" href=\"UTD.htm?41/45/42715\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some specialists administer a single dose of 2.4 million units of benzathine penicillin IM at the end of the two week IV course to extend the duration of therapy for late disease. An alternative regimen to IV penicillin is procaine penicillin (2.4 million units IM given daily) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    (500 mg orally four times daily), both for 10 to 14 days.",
"   </p>",
"   <p>",
"    Symptomatic relapse after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    therapy for neurosyphilis has been reported in the pre-HAART and post-HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. For this reason, some experts prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    therapy for neurosyphilis, but no large studies have been done to alter recommendations for penicillin as first line therapy and there are scarce data regarding this approach in HIV-infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Latent syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with latent syphilis should be treated according to the stage-specific recommendations for HIV-seronegative persons. &ldquo;Early latent&rdquo; syphilis infers diagnosis within one year of infection in an asymptomatic patient, while &ldquo;late&rdquo; latent infection is anytime afterwards.",
"   </p>",
"   <p>",
"    The recommended therapy for latent syphilis is benzathine penicillin (2.4 million units intramuscular); one-dose therapy is given for early latent syphilis while three weekly doses are recommended for late latent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     JARISCH-HERXHEIMER REACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Jarisch-Herxheimer reaction is an acute febrile reaction that usually occurs within the first 24 hours after any therapy for syphilis. The fever may be accompanied by headache, myalgias, rigors, sweating, hypotension, and the worsening of rash if initially present. These symptoms often resolve without intervention within 12 to 24 hours. It occurs most often after treatment of early syphilis. Mechanisms of how this reaction develops are not completely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV coinfection has not been associated with increased or more severe Jarisch-Herxheimer reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/19\">",
"     19",
"    </a>",
"    ]. Although there is no prevention for this reaction, patients should be informed of the possible signs and symptoms and advised to contact their clinicians if a severe reaction occurs. There is no effective prevention for this reaction, but antipyretics may be used if symptoms arise and may reduce symptom severity and duration of the reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PENICILLIN ALLERGIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syphilis in the HIV-infected penicillin allergic patient should be managed the same way as in the HIV-uninfected patient. When alternative agents to penicillin are used, close follow-up is essential, regardless of HIV status. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Patient monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Allergy consultation is recommended in patients with a history of serious penicillin allergy if an agent with potential cross-reactivity (eg, cephalosporin) is being considered. A brief overview of the approach to the treatment of syphilis in the HIV-infected penicillin allergic patient is found below; a detailed discussion is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\", section on 'Approach to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary and secondary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin allergic patients may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/4\">",
"     4",
"    </a>",
"    ]. Preliminary data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    may also be effective regimens for primary and secondary syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Recommendations for treatment dosing and duration are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, reports of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    resistance are increasing in the United States and Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Such findings suggest that the use of azithromycin for syphilis treatment should be limited in areas where resistance is common. These data are particularly relevant to the HIV-infected patient who may be taking macrolides for MAC prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In penicillin allergic HIV-infected persons with neurosyphilis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    may be given, although the possibility of cross reactive hypersensitivity should be considered, especially in patients with serious penicillin allergies. Recommendations for treatment dosing and duration and the management of the penicillin allergic patient are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\", section on 'Approach to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Latent syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative regimens for penicillin allergic patients with latent syphilis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    . These regimens have not been studied in HIV-infected patients and should be considered with caution. Recommendations for treatment dosing and duration and the management of the penicillin allergic patient are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\", section on 'Approach to therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of HIV status, the CDC recommends careful monitoring of patients with syphilis after therapy, although some studies demonstrate that appropriate follow-up is often lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A baseline VDRL or RPR titer should be drawn on the day of treatment or within two weeks before treatment. This titer is used for comparison to subsequent titers that are obtained on treatment to assess response. The expected serologic response varies by stage and is discussed below. &nbsp;",
"   </p>",
"   <p>",
"    Regardless of HIV status, after successful treatment for syphilis, 15 to 20 percent of persons might remain \"serofast\", meaning that serum nontreponemal test titers remain reactive at low and unchanging titers, generally &lt;1:8, for extended periods of times [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/9\">",
"     9",
"    </a>",
"    ]. The clinical significance of the serofast state is unclear.",
"   </p>",
"   <p>",
"    However, a fourfold increase in titer above the established serofast baseline indicates potential reinfection or treatment failure and requires further evaluation, including a cerebral spinal fluid examination. If the CSF examination is normal, treatment with benzathine penicillin administered as 2.4 million units intramuscularly at weekly intervals for three weeks is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/3\">",
"     3",
"    </a>",
"    ]. If the CSF is abnormal, then treatment for neurosyphilis would be indicated.",
"   </p>",
"   <p>",
"    Maintaining communication with local or state health departments to verify a patient's latest reported titer and treatment record, which is on file, can assist in further evaluation. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expected results from routine patient monitoring during the various stages of syphilis are discussed below. There are also data that serologic responses may be altered in HIV-infected patients. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Serologic responses'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Primary and secondary syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with primary or secondary syphilis should be followed closely at three-month intervals during the year after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/1\">",
"     1",
"    </a>",
"    ]. A fourfold change in titer, equivalent to a change of two dilutions (such as from 1:32 to 1:8) is considered as an adequate therapeutic response if documented within 6 to 12 months after treatment for primary syphilis. Longer periods of time are required for follow-up of patients with secondary or tertiary syphilis. Nontreponemal test titers may also decline more slowly in patients with previous syphilis infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Latent syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In HIV-infected patients with latent syphilis, clinical and serologic follow-up evaluations should be done at six-month intervals for a two-year period. If by 12 to 24 months, nontreponemal titers have not declined fourfold, CSF evaluation should be repeated with treatment administered accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/1\">",
"     1",
"    </a>",
"    ]. While titers may decline fourfold by 12 to 24 months if the initial value is &ge;1:32, it is not uncommon for such a decrease to require 24 months in HIV-infected patients (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Serologic responses'",
"    </a>",
"    below). One study reported a trend for increased treatment failure in late latent",
"    <span class=\"nowrap\">",
"     syphilis/unknown",
"    </span>",
"    duration among the HIV-seropositive group compared to HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of clinical symptoms or a fourfold rise in nontreponemal titers should prompt a repeat CSF evaluation and retreatment as indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If CSF pleocytosis was present before treatment, a CSF examination should be repeated every six months until the cell count is normal. Abnormalities of protein and VDRL-CSF test titers can also be monitored, but are slower to normalize [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. However, if the CSF is not normal two years after treatment, retreatment should be considered.",
"   </p>",
"   <p>",
"    One study suggested that patients with CD4 counts &lt;200 cells were 3.7 times less likely to normalize CSF VDRL results than were those patients with higher CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study of 110 patients with early or late neurosyphilis (78 percent of whom had HIV infection) suggested that normalization of serum RPR titers predicted normalization of CSF after treatment in HIV-seronegative patients; the correlation was less accurate in patients with HIV, particularly those who were not taking ART [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/12\">",
"     12",
"    </a>",
"    ]. The study was limited by its observational nature, varying treatment regimens, and uncertainty regarding the number of patients with well-defined neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard definitions of treatment failure, regardless of HIV status, include recurrence or persistence of symptoms, lack of a fourfold decrease in nontreponemal test titers at 24 months after treatment of late syphilis or a fourfold increase in nontreponemal test titers at any time after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SEROLOGIC RESPONSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that evaluate the association between HIV infection and poor serologic response following syphilis treatment have yielded mixed results. In one study that compared serological response to syphilis treatment in HIV-infected and HIV-uninfected patients attending STD clinics, HIV-infected patients were less likely to have a fourfold drop in RPR titer and have a longer time to successful serological response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, in a randomized controlled trial of enhanced therapy for early syphilis in patients with and without HIV, HIV-infected patients with primary and secondary syphilis responded less well serologically than the patients without HIV infection, but clinically defined failure was uncommon in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/9\">",
"     9",
"    </a>",
"    ]. Rates of serologically defined treatment failure for HIV-infected patients with primary syphilis were significantly higher than for those without HIV at six months (22 versus 5 percent) with a trend still present at 12 months (14 versus 8 percent). There were also more serologic treatment failures among HIV-infected patients with secondary syphilis (23 versus 10 percent and 19 versus 6 percent at six and 12 months, respectively); the results at 12 months were statistically significant. In this study, rates of serologically defined treatment failure were similar between HIV-infected patients with CD4 percentages higher or lower than 14 percent.",
"   </p>",
"   <p>",
"    However, the above study was performed prior to the widespread use of combination antiretroviral therapy (ART). Subsequent studies have suggested that the risk of poor serologic response in the setting of HIV infection may be attenuated by the use of ART or the absence of significant immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/13,27\">",
"     13,27",
"    </a>",
"    ]. As an example, in a prospective study of 180 HIV-infected patients who experienced 231 cases of syphilis from 1990 through 2006, a total of 71 episodes of serologic failure were documented [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/13\">",
"     13",
"    </a>",
"    ]. A CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    at the time of syphilis diagnosis was associated with an increased risk of serologic failure (adjusted HR, 2.88; 95% CI 1.26-4.88), whereas receipt of ART was associated with a 60 percent reduction in the rate of serologic failure (adjusted HR, 0.40; 95% CI 0.21-0.75) independent of the CD4 T-cell response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SCREENING AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All HIV-infected persons should be tested for syphilis. Current recommendations advise to test HIV-infected persons for syphilis upon entry to HIV-related care, on a yearly basis, and more frequently as indicated by ongoing risk behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk behaviors associated with increased likelihood of becoming infected with syphilis include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19415/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple sex partners",
"     </li>",
"     <li>",
"      Anonymous sex partners including those met through the internet and circuit parties",
"     </li>",
"     <li>",
"      Engaging in sex in exchange for drugs or money",
"     </li>",
"     <li>",
"      Injection drug use or use of \"club drugs\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of HIV status, persons exposed sexually to a patient who has syphilis in any stage should be evaluated clinically and serologically. Any person exposed within 90 day preceding the diagnosis of primary, secondary or early latent syphilis in a sex partner, or exposed to a sex partner with a high nontreponemal serologic test titer (&ge;1:32), should be presumptively treated for syphilis, regardless of his or her own syphilis serologic test results. If a person was exposed to someone with primary, secondary, or early latent syphilis more than 90 days before the diagnosis, presumptive treatment for syphilis should be given if serologic tests are not available immediately or follow-up is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to the treatment of syphilis in the HIV-infected patient is similar to the approach in the HIV-seronegative host; penicillin is the drug of choice. The preparation of penicillin, route of administration, dose, and duration of therapy depends upon the stage of disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients with primary, secondary, or early latent syphilis should receive benzathine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (2.4 million units IM) in a single dose (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with late latent syphilis, or the more common latent syphilis of unknown duration, should receive benzathine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (2.4 million units IM) weekly for three consecutive weeks. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurosyphilis should be treated with aqueous crystalline",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (3 to 4 million units IV every four hours or as a continuous infusion for a total daily dose of 18 to 24 million units) for 14 days. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.) An additional dose of IM benzathine penicillin (2.4 million units) may be considered at the end of the treatment course to complete three weeks of therapy for late disease.",
"     </li>",
"     <li>",
"      HIV coinfection has not been associated with increased or more severe Jarisch-Herxheimer reactions. Antipyretics may be used if symptoms arise. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Jarisch-Herxheimer reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the penicillin allergic patient is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H26#H26\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathogenesis, clinical manifestations, and treatment of late syphilis\", section on 'Approach to therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      All HIV-infected patients should have baseline and follow-up serologies performed to monitor response to therapy. Patients with neurosyphilis also need follow-up CSF evaluation. Close follow-up is particularly important in the penicillin allergic patient who is treated with an alternative regimen. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic responses appear slower in HIV-infected patients; the clinical significance of this is unclear. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Serologic responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all HIV-infected patients be tested for syphilis on entry to care and on a yearly basis thereafter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients may require more frequent testing as appropriate for their risk behaviors. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Screening and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/1\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/2\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/std/treatment/2010/default.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/4\">",
"      Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis 2006; 42:e45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/5\">",
"      Long CM, Klausner JD, Leon S, et al. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru. Sex Transm Dis 2006; 33:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/6\">",
"      Marra CM, Boutin P, McArthur JC, et al. A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000; 30:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/7\">",
"      Wong T, Singh AE, De P. Primary syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin. Am J Med 2008; 121:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/8\">",
"      Gutierrez-Galhardo MC, do Valle GF, S&aacute; FC, et al. Clinical characteristics and evolution of syphilis in 24 HIV+ individuals in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 2005; 47:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/9\">",
"      Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997; 337:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/10\">",
"      Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 2007; 83:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/11\">",
"      Ghanem KG, Moore RD, Rompalo AM, et al. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008; 22:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/12\">",
"      Marra CM, Maxwell CL, Tantalo LC, et al. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 2008; 47:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/13\">",
"      Ghanem KG, Moore RD, Rompalo AM, et al. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis 2008; 47:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/14\">",
"      Gonz&aacute;lez-L&oacute;pez JJ, Guerrero ML, Luj&aacute;n R, et al. Factors determining serologic response to treatment in patients with syphilis. Clin Infect Dis 2009; 49:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/15\">",
"      Gaudio PA. Update on ocular syphilis. Curr Opin Ophthalmol 2006; 17:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/16\">",
"      Gordon SM, Eaton ME, George R, et al. The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection. N Engl J Med 1994; 331:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/17\">",
"      Walter T, Lebouche B, Miailhes P, et al. Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis 2006; 43:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/18\">",
"      Pound MW, May DB. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 2005; 30:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/19\">",
"      Yang CJ, Lee NY, Lin YH, et al. Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the hiv infection epidemic: incidence and risk factors. Clin Infect Dis 2010; 51:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/20\">",
"      Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005; 353:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/21\">",
"      Bai ZG, Yang KH, Liu YL, et al. Azithromycin vs. benzathine penicillin G for early syphilis: a meta-analysis of randomized clinical trials. Int J STD AIDS 2008; 19:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/22\">",
"      Marra CM, Colina AP, Godornes C, et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis 2006; 194:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/23\">",
"      Mitchell SJ, Engelman J, Kent CK, et al. Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. Clin Infect Dis 2006; 42:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/24\">",
"      Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004; 351:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/25\">",
"      Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis 2004; 38:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/26\">",
"      Musher DM. Neurosyphilis: diagnosis and response to treatment. Clin Infect Dis 2008; 47:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/27\">",
"      Knaute DF, Graf N, Lautenschlager S, et al. Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis 2012; 55:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/29\">",
"      Cohen CE, Winston A, Asboe D, et al. Increasing detection of asymptomatic syphilis in HIV patients. Sex Transm Infect 2005; 81:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19415/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis--United States, 2002. MMWR Morb Mortal Wkly Rep 2003; 52:1117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7600 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19415=[""].join("\n");
var outline_f18_61_19415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29143887\">",
"      Impact of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary and secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Latent syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      JARISCH-HERXHEIMER REACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PENICILLIN ALLERGIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary and secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Latent syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Primary and secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Latent syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SEROLOGIC RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SCREENING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7600|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/18/37152\" title=\"algorithm 1\">",
"      Dx rx syphilis algorithm I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7600|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/45/42715\" title=\"table 1\">",
"      Treatment and monitoring of neurosyphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_61_19416="Acute appendicitis in children: Diagnostic imaging";
var content_f18_61_19416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute appendicitis in children: Diagnostic imaging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19416/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19416/contributors\">",
"     George A Taylor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19416/contributors\">",
"     David E Wesson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19416/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19416/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/61/19416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendicitis is the most common condition in children requiring emergency abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/1\">",
"     1",
"    </a>",
"    ]. The key to a successful outcome has always been early diagnosis followed by appendectomy before gangrene or perforation develops. Nevertheless, confirming the diagnosis of appendicitis and avoiding the risks of unnecessary surgery continue to be a challenge, particularly in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging plays an important role in the evaluation of patients who do not present with the classic signs and symptoms of appendicitis but in whom the diagnosis is being considered. Ultrasonography (US) and computed tomography (CT), separately or in combination, are the modalities used most frequently. In addition, there are data that suggest that using an imaging protocol improves diagnostic accuracy.",
"   </p>",
"   <p>",
"    This topic will review diagnostic imaging for acute appendicitis in children. The epidemiology, clinical features, diagnosis, and treatment of appendicitis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31785?source=see_link\">",
"     \"Acute appendicitis in children: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5842759\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children who have atypical or equivocal findings for appendicitis on physical examination and laboratory testing, imaging may be helpful to establish or exclude the diagnosis. Ultrasonography (US) and computed tomography (CT), separately or in combination, are the modalities used most frequently. A systematic institutional approach to the choice of imaging may improve outcomes. (See",
"    <a class=\"local\" href=\"#H4189022\">",
"     'Clinical protocols'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, imaging is not warranted in most children who are unlikely to have appendicitis based upon the clinical examination and laboratory studies. Similarly, children with a typical clinical presentation for acute appendicitis are likely to have appendicitis. In this circumstance, clinicians should consult a surgeon with experience caring for children rather than obtaining imaging studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H6659013#H6659013\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Impact on diagnostic outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In settings where operative care for children with appendicitis is not available, resources for appropriate pediatric imaging and interpretation of radiographic findings may also be lacking. Clinicians managing children with suspected appendicitis in such facilities, whenever possible, should avoid diagnostic imaging and instead transfer the patient to a center with pediatric radiology and pediatric general surgery capabilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4189022\">",
"    <span class=\"h1\">",
"     CLINICAL PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Institutions should develop imaging protocols that they can utilize effectively. Both ultrasonography (US) and computed tomography (CT) are valuable modalities for imaging in children with suspected appendicitis. Preliminary evidence also suggests a potential role for magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/3\">",
"     3",
"    </a>",
"    ]. The choice of study in any given clinical situation depends upon patient characteristics, such as obesity and gender, and institutional resources, such as the availability of US and CT and the expertise of the staff [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/4\">",
"     4",
"    </a>",
"    ]. Of note, clinicians may be reluctant to use a protocol that includes modalities that are frequently unavailable or cannot be interpreted with confidence.",
"   </p>",
"   <p>",
"    The utility of an institution-specific protocol was demonstrated in a report describing 861 children evaluated in a tertiary urban children's hospital emergency department (ED) for suspected appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/5\">",
"     5",
"    </a>",
"    ]. US with graded compression was performed initially. If the appendix was not visualized or the interpretation of the study was equivocal, a focused CT with rectal contrast was performed. These results were compared with a similar group of 920 patients seen in the ED before the protocol was implemented. Institution of the protocol was associated with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased diagnosis of appendicitis (79 versus 57 percent)",
"     </li>",
"     <li>",
"      Decreased rate of perforated appendix (16 versus 35 percent)",
"     </li>",
"     <li>",
"      Decreased rate of negative appendectomy (4 versus 15 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this study shows the benefit of institution-specific protocols, most centers favor intravenous rather than rectal contrast when performing abdominal CTs in children. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Contrast'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In an observational study from a children&rsquo;s hospital that evaluated the impact of a staged imaging protocol for appendicitis, 46 to 57 percent adherence was reported with an agreed upon imaging protocol that emphasized US and proceeded to CT with IV contrast only if US was equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/6\">",
"     6",
"    </a>",
"    ]. Among the 631 children in whom imaging was performed in compliance with the protocol, the following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity and specificity for identifying appendicitis were 99 and 91 percent, respectively.",
"     </li>",
"     <li>",
"      Rates of negative appendectomies and missed appendicitis were 8 and 0.5 percent, respectively.",
"     </li>",
"     <li>",
"      CT was avoided in 53 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, imaging protocols for the diagnosis of appendicitis in children can result in a significant decrease in radiation exposure without sacrificing diagnostic accuracy or clinical outcomes. However, even in settings where multidisciplinary protocols have been developed, achieving high rates of compliance can be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4189074\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that imaging in children with atypical or equivocal findings for appendicitis begin with ultrasonography (US). If the appendix is not visualized or the findings on US are otherwise not diagnostic, the patient may either be observed with serial physical examinations and repeated imaging (US, computed tomography, or magnetic resonance imaging [MRI]) performed at a later time if a clinical diagnosis of appendicitis cannot be made or, if more prompt diagnosis is desired, the patient may directly proceed to contrast-enhanced computed tomography (CT) or MRI. If a CT is performed, we use intravenous contrast alone and begin the evaluation with a focused examination and expand the study to include the entire abdomen if an abnormality is seen on the uppermost image. When reviewing the images, coronal reformatted images increase the level of confidence in identification of the normal and abnormal appendix [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Contrast'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Focused CT'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The American College of Radiology recommends US, followed by CT as needed, as the imaging protocol of choice for children with suspected appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/8\">",
"     8",
"    </a>",
"    ]. In the United States, increased use of ultrasound alone or ultrasound with CT in children&rsquo;s hospitals was associated with lower rates of negative appendectomy without an increase in appendiceal rupture or patients returning with a new diagnosis of appendicitis within two weeks of initial emergency department visit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/9\">",
"     9",
"    </a>",
"    ]. In Israel, increased use of US for diagnosis of acute appendicitis in the emergency department significantly decreased pediatric hospital admissions without any instance of missed appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/10\">",
"     10",
"    </a>",
"    ]. In settings with adequate experience in interpreting MRI for the presence of appendicitis and with the resources to rapidly obtain and interpret the study, MRI may be preferable to CT.",
"   </p>",
"   <p>",
"    While we encourage radiology departments to develop expertise in US for children, we recognize that the availability of such expertise may be limited in some locations. &nbsp;",
"   </p>",
"   <p>",
"    Given the technical limitations of ultrasound in diagnosing appendicitis in obese children, some clinicians may choose to perform contrast CT as the initial imaging strategy in this population. However, US for initial diagnostic imaging in obese children may avoid the need for CT in a large proportion of these patients. As an example, in a small observational study that evaluated outcomes for 76 obese children undergoing US for suspected appendicitis, appendicitis was confirmed by US alone in 23 of 26 patients and was excluded in 42 of 50 patients without the use of CT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ULTRASONOGRAPHY (US)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography (US) is available in most institutions, is relatively inexpensive, and is safe. It has the added advantage of identifying ovarian pathology, such as torsion or an ovarian cyst. However, accuracy depends upon the skill and experience of the sonographer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4189194\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;US improves diagnostic accuracy in selected children with suspected appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/12\">",
"     12",
"    </a>",
"    ]. In studies that only evaluated pediatric patients, sensitivities have been variable, ranging from 74 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/12-19\">",
"     12-19",
"    </a>",
"    ]. Specificities ranging from 88 to 99 percent have also been reported. In a metaanalysis of 26 studies that evaluated the diagnostic performance of ultrasonography for the diagnosis of appendicitis in adults and children, among the 9356 children studied, pooled sensitivities and specificities were 88 percent (95% CI 86-90) and 94 percent (95% CI 92-95), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, US may also result in a significant number of false positive and false negative results. For example, in an observational study of 263 children, 4 to 17 years of age, with suspected appendicitis, US was inaccurate in 101 examinations (88 false positive findings, 13 false negative findings) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/21\">",
"     21",
"    </a>",
"    ]. Inaccurate examinations were significantly associated with high body mass index (&ge;85",
"    <sup>",
"     th",
"    </sup>",
"    percentile) or low pretest clinical suspicion for appendicitis (OR 2.0, 95% CI 1.1-3.5 and OR 2.4, 95% CI 1.4-4.0, respectively).",
"   </p>",
"   <p>",
"    The diagnosis of appendicitis",
"    <strong>",
"     cannot",
"    </strong>",
"    be reliably excluded unless a normal appendix is seen. Reported visualization rates vary from 22 percent to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Factors that affect this variability primarily include the experience and technique of the sonographer, as well as the child&rsquo;s body habitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques have been described that may improve visualization of the appendix and more accurately diagnose appendicitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Posterior compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of posterior manual compression to graded compression can help to identify the appendix. This was demonstrated in a report of 570 consecutive patients referred for suspected appendicitis, 28 percent of whom were less than 16 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/22\">",
"     22",
"    </a>",
"    ]. Visualization of the appendix increased from 85 to 95 percent with posterior manual compression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Positional scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scanning in the flank and pelvis, in addition to the right lower quadrant, may be useful. Among 199 children with appendicitis, scanning of the retrocecal area using a posterolateral approach, followed by scanning of the pelvis through a full urinary bladder, and scanning of the right lower quadrant resulted in identification of 68 percent of abnormal appendices [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/14\">",
"     14",
"    </a>",
"    ]. The combination of noncompressive and compressive techniques increased the identification rate to 96 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pitfalls and limitations of US",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of difficulties with the use of ultrasound for the diagnosis of acute appendicitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fat absorbs and diffuses the ultrasound beam making it more difficult to scan overweight children.",
"     </li>",
"     <li>",
"      It can be difficult to identify a normal appendix or one that is only focally inflamed (\"tip\" appendicitis). Therefore, a negative ultrasound examination in the presence of persistent symptoms is not sufficient to reliably exclude appendicitis.",
"     </li>",
"     <li>",
"      Pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anxiety may make sonographic imaging of the abdomen difficult or impossible in some children.",
"     </li>",
"     <li>",
"      Most institutions have limited or no access to staff trained to perform ultrasound in children during all hours of operation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sonographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound findings that support the diagnosis of appendicitis include the following (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52767 \" href=\"UTD.htm?19/50/20263\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56139 \" href=\"UTD.htm?43/43/44735\">",
"     image 2",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61146 \" href=\"UTD.htm?2/5/2139\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Noncompressible tubular structure in right lower quadrant",
"     </li>",
"     <li>",
"      Wall thickness of the appendix greater than 2 mm",
"     </li>",
"     <li>",
"      Overall diameter greater than 6 mm",
"     </li>",
"     <li>",
"      Free fluid in the right lower quadrant",
"     </li>",
"     <li>",
"      Thickening of the mesentery",
"     </li>",
"     <li>",
"      Localized tenderness with graded compression",
"     </li>",
"     <li>",
"      Presence of a calcified appendicolith",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A small number of children with a normal appendix visualized on ultrasound may have early, or tip, appendicitis. How often this occurs is unknown. Consequently, clinical correlation and imaging with CT may be required to exclude the diagnosis of appendicitis, even with a normal US examination.",
"   </p>",
"   <p>",
"    Diagnoses that can mimic appendicitis on US include lymphoma, Crohn's disease, and cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, we have seen some false-positive ultrasound reports where the diagnosis of appendicitis was based upon increased appendiceal wall thickness alone. We recommend caution in interpreting ultrasound reports without other evidence for the diagnosis.",
"   </p>",
"   <p>",
"    In our practice, visualization of a normal appendix constitutes a normal US examination. When the appendix is not visualized in an otherwise unremarkable pelvic examination, we report the study as showing no evidence of appendicitis. At that time, we will almost always go to CT for a final diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPUTED TOMOGRAPHY (CT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is the preferred imaging modality for testing of children with possible appendicitis who have equivocal findings on ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/1\">",
"     1",
"    </a>",
"    ]. It is typically more available and less operator dependent than ultrasonography (US). CT is also useful in establishing alternative diagnoses for abdominal pain. As an example, in one observational study of 125 children examined with focused CT that was negative for possible appendicitis, 62 had alternative diagnoses made including ileitis or colitis suggestive of inflammatory bowel disease, mesenteric adenitis, and intact or ruptured ovarian cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19883812\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies in which only children were enrolled, sensitivity for the diagnosis of acute appendicitis by computed tomography (CT) ranges between 95 and 100 percent. [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/13,15,16,24\">",
"     13,15,16,24",
"    </a>",
"    ]. Reported specificity is 93 to 100 percent. In a meta-analysis of 26 studies that evaluated the diagnostic performance of computed tomography for the diagnosis of appendicitis in adults and children, among the 9356 children, pooled sensitivities and specificities were 94 percent (95% CI 92-97) and 95 percent (95% CI 94-97), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT has the disadvantage of exposure to ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. In addition, some children have a paucity of mesenteric fat, which makes visualization of either a normal or an inflamed appendix more difficult, especially on an unenhanced CT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques to improve the accuracy and safety of CT include the use of intravenous contrast, limiting the examination to a focused CT of the pelvic contents, and adjusting scanning parameters to achieve the lowest radiation dose possible while maintaining diagnostic accuracy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with suspected appendicitis and equivocal findings on ultrasound who proceed directly to computed tomography (CT) undergo contrast-enhanced CT with intravenous contrast rather than no contrast. In addition, we recommend that children with suspected appendicitis undergo contrast-enhanced computed tomography (CT) with intravenous contrast alone rather than intravenous contrast combined with enteral (oral or rectal) contrast.",
"   </p>",
"   <p>",
"    Intravenous contrast is helpful in identifying the appendix and adjacent structures, particularly in children under the age of 10 years who generally have limited mesenteric fat. For example, in 306 children with suspected appendicitis who underwent both unenhanced helical CT of the lower abdomen and intravenous contrast-enhanced CT of the entire abdomen, contrast-enhanced CT had a significantly higher pooled sensitivity for appendicitis than unenhanced CT (90 versus 66 percent, respectively) with similar specificity (94 versus 96 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19883812\">",
"     'Test performance'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    In addition, if a child with suspected appendicitis has equivocal or negative findings on an unenhanced CT, then frequently the study is repeated with contrast, thus increasing radiation exposure.",
"   </p>",
"   <p>",
"    Contrast has also been given enterally (rectal or oral), to opacify and distend the cecum in an attempt to improve visualization of the inflamed appendiceal wall or mesentery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/13,16,31\">",
"     13,16,31",
"    </a>",
"    ]. However, observational studies suggest that rectal or oral contrast do not further improve test performance over intravenous contrast CT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19883812\">",
"     'Test performance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Furthermore, enteral contrast administration presents several challenges. Rectal contrast administration is uncomfortable, difficult to administer in patients with diarrhea, and contraindicated in patients with intestinal perforation. Oral contrast delays scanning for approximately two hours, does not appear in the terminal ileum in up to 30 percent of patients at the time of CT scan, and may require nasogastric tube placement for proper administration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous contrast can cause hypersensitivity reactions, chemotoxicity, and renal failure. However, these reactions are rare in children. The risk of contrast-induced immediate hypersensitivity can be reduced by using low osmolal contrast material agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23124?source=see_link\">",
"     iodixanol",
"    </a>",
"    [Visipaque&reg;]) and, in children with asthma, ensuring control of symptoms before the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link&amp;anchor=H8#H8\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link&amp;anchor=H13#H13\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\", section on 'Primary prevention of IHRs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Focused CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CT scan limited to the lower abdomen may be sufficient to diagnose appendicitis, while exposing the child to less radiation. Some experts advocate scanning from the bottom of the third lumbar vertebral body to the pubic ramus. The scan can be expanded to include the upper abdomen if an abnormality is found on the initial uppermost image [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for this approach was demonstrated in a retrospective review of 93 abdominal CT scans obtained with oral and IV contrast in children with suspected appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/34\">",
"     34",
"    </a>",
"    ]. All of the abnormal findings leading to a diagnosis of appendicitis were located below the lower pole of the right kidney (RLP). In addition, there was no difference between the sensitivity and specificity for CT of the entire abdomen compared with CT below RLP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     CT scanning parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scanning parameters, such as the tube current setting (in milliamperes) and pitch (table speed), should be adjusted based upon patient weight or girth to reduce radiation dose [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/28,35-38\">",
"     28,35-38",
"    </a>",
"    ]. Weight-based reductions in tube current have been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, radiation dose can be significantly reduced by increasing pitch.",
"   </p>",
"   <p>",
"    Awareness of these recommendations may not be widespread, however. One report described the scanning parameters used for body CT examinations that had been obtained at referring hospitals and were then sent to a children's hospital for further review [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/40\">",
"     40",
"    </a>",
"    ]. Mean tube current settings exceeded weight-based recommendations in all age groups, and 53 percent of studies were performed without an adjustment in pitch.",
"   </p>",
"   <p>",
"    Important information on opportunities to reduce radiation dose during CT imaging in children can be found on the",
"    <em>",
"     &ldquo;Image Gently&rdquo;",
"    </em>",
"    website [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pitfalls and limitations of CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several limitations to the use of CT for the diagnosis of appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scanning performed in institutions not familiar with pediatric protocols may result in the excessive use of radiation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'CT scanning parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A normal appendix is more difficult to visualize in children with less intraperitoneal fat.",
"     </li>",
"     <li>",
"      A fluid-filled loop of small bowel may be misinterpreted as an inflamed appendix.",
"     </li>",
"     <li>",
"      An appendicolith can be obscured by intestinal contrast.",
"     </li>",
"     <li>",
"      A Meckel's diverticulum can be misinterpreted as an enlarged appendix.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     CT findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of appendicitis is unlikely if the appendix is not identified as a separate structure on CT and there are no additional signs of inflammation in surrounding structures. Findings on CT that support the diagnosis of appendicitis include (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70709 \" href=\"UTD.htm?4/42/4771\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58384 \" href=\"UTD.htm?3/1/3099\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wall thickness greater than 2 mm",
"     </li>",
"     <li>",
"      Appendicolith",
"     </li>",
"     <li>",
"      Enlargement of the appendix",
"     </li>",
"     <li>",
"      Concentric thickening of the appendiceal wall (target sign)",
"     </li>",
"     <li>",
"      Phlegmon",
"     </li>",
"     <li>",
"      Abscess",
"     </li>",
"     <li>",
"      Free fluid",
"     </li>",
"     <li>",
"      Thickening of the mesentery, fat stranding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other pathological processes that involve the appendix and can look like acute appendicitis on imaging studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crohn's disease and lymphoma may be indistinguishable from appendicitis on CT.",
"     </li>",
"     <li>",
"      Patients with cystic fibrosis may have a markedly enlarged appendix filled with mucus or stool without acute appendicitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22931363\">",
"    <span class=\"h1\">",
"     MAGNETIC RESONANCE IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data suggest that magnetic resonance imaging (MRI) without contrast can provide similar diagnostic accuracy as computed tomography without radiation exposure or excessive time delay (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86410 \" href=\"UTD.htm?4/52/4930\">",
"     image 4",
"    </a>",
"    ). As an example, in an observational study of 208 children between three and 17 years of age with suspected appendicitis (40 pathologically proven cases of appendicitis), MRI without contrast using four sequence axial and coronal T2 and coronal inversion recovery sequences had a sensitivity and specificity of 98 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/3\">",
"     3",
"    </a>",
"    ]. The total median time from request to radiology report was 123 minutes. The median imaging time was 14 minutes. In this study, MRI was the sole imaging test.",
"   </p>",
"   <p>",
"    In settings with adequate experience in interpreting MRI for the presence of appendicitis and with the resources to rapidly obtain and interpret the study, MRI may be preferable to CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PLAIN RADIOGRAPHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs of the abdomen are of little value for the evaluation of patients with suspected appendicitis, unless there is clinical evidence of bowel obstruction or perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19416/abstract/42\">",
"     42",
"    </a>",
"    ]. Nevertheless, plain films may occasionally show secondary signs in acute appendicitis, such as a fecalith, or suggest an alternative diagnosis, such as basilar pneumonia (",
"    <a class=\"graphic graphic_table graphicRef60537 \" href=\"UTD.htm?0/45/731\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36129?source=see_link\">",
"       \"Patient information: Appendicitis in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/37/3666?source=see_link\">",
"       \"Patient information: Appendicitis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging may be helpful for further evaluation of children with atypical or equivocal findings for appendicitis after physical examination and laboratory studies. Ultrasonography (US) and computed tomography (CT), separately or in combination, are the modalities used most frequently. Children with clinical examinations and laboratory studies that do not suggest appendicitis should",
"      <strong>",
"       not",
"      </strong>",
"      undergo imaging. Children with physical findings that are highly suggestive of appendicitis should undergo evaluation by a surgeon rather than imaging. (See",
"      <a class=\"local\" href=\"#H5842759\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H5#H5\">",
"       \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Institutions should develop imaging protocols that they can utilize effectively. Such protocols have been associated with increased diagnosis of appendicitis at initial presentation, decreased negative appendectomy rate, and no increase in perforation rate. (See",
"      <a class=\"local\" href=\"#H4189022\">",
"       'Clinical protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that imaging in children with atypical or equivocal findings for appendicitis begin with ultrasonography (US). If the appendix is not visualized or the findings on US are otherwise not diagnostic, the patient may either be observed with serial physical examinations and repeated imaging (US or CT) performed at a later time if a clinical diagnosis of appendicitis cannot be made or, if more prompt diagnosis is desired, the patient may directly proceed to contrast-enhanced computed tomography (CT). We begin the CT evaluation with the pelvis (third lumbar vertebra to pubic ramus) and expand the study to include the entire abdomen if an abnormality is seen on the uppermost image. Given the limitation of ultrasound in obese children, some clinicians may choose to perform contrast CT as the initial imaging strategy in this population. (See",
"      <a class=\"local\" href=\"#H4189074\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Focused CT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with suspected appendicitis and equivocal findings on ultrasound undergo contrast-enhanced computed tomography (CT) with intravenous contrast rather than no contrast. In addition, we suggest that these children undergo contrast-enhanced computed tomography (CT) with intravenous contrast alone rather than intravenous contrast combined with enteral (oral or rectal) contrast. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Contrast'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      US is a highly specific test for diagnosing appendicitis, but sensitivity has been low in some reports (",
"      <a class=\"graphic graphic_table graphicRef61146 \" href=\"UTD.htm?2/5/2139\">",
"       table 1",
"      </a>",
"      ). A normal appendix must be seen in order to reliably exclude appendicitis in a patient with persistent symptoms. The ability to accomplish this varies with patient body habitus and with operator technique and experience. Various techniques have been reported to improve visualization of the appendix. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      US is particularly useful in peri- and postpubertal females to identify alternative gynecologic diagnoses, such as ovarian cyst or ovarian torsion. It is less reliable in obese children because fat absorbs and diffuses the ultrasound beam. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ultrasonography (US)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound findings that support the diagnosis of appendicitis are summarized in the table (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52767 \" href=\"UTD.htm?19/50/20263\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56139 \" href=\"UTD.htm?43/43/44735\">",
"       image 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef58384 \" href=\"UTD.htm?3/1/3099\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sonographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CT is less operator dependent than US. It also may be more sensitive and specific for the diagnosis of appendicitis than US (",
"      <a class=\"graphic graphic_table graphicRef61146 \" href=\"UTD.htm?2/5/2139\">",
"       table 1",
"      </a>",
"      ). CT has the disadvantage of exposure to ionizing radiation. In addition, some children have a paucity of mesenteric fat, which makes visualizing either a normal or an inflamed appendix more difficult. CT findings that support the diagnosis of appendicitis are summarized in the table (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70709 \" href=\"UTD.htm?4/42/4771\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60537 \" href=\"UTD.htm?0/45/731\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Computed tomography (CT)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'CT findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Techniques, such as focused CT, and modifying CT scan parameters, such as tube currents and table speed, can reduce radiation exposure. When using CT, we recommend that radiation doses be adjusted as much as possible without compromising the accuracy of the study. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Focused CT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'CT scanning parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs of the abdomen are of little value for the evaluation of patients with suspected appendicitis, unless there is clinical evidence of bowel obstruction or perforation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Plain radiographs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/1\">",
"      Sivit CJ. Imaging the child with right lower quadrant pain and suspected appendicitis: current concepts. Pediatr Radiol 2004; 34:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/2\">",
"      Flum DR, Koepsell T. The clinical and economic correlates of misdiagnosed appendicitis: nationwide analysis. Arch Surg 2002; 137:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/3\">",
"      Moore MM, Gustas CN, Choudhary AK, et al. MRI for clinically suspected pediatric appendicitis: an implemented program. Pediatr Radiol 2012; 42:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/4\">",
"      Taylor GA. Suspected appendicitis in children: in search of the single best diagnostic test. Radiology 2004; 231:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/5\">",
"      Pe&ntilde;a BM, Taylor GA, Fishman SJ, Mandl KD. Effect of an imaging protocol on clinical outcomes among pediatric patients with appendicitis. Pediatrics 2002; 110:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/6\">",
"      Krishnamoorthi R, Ramarajan N, Wang NE, et al. Effectiveness of a staged US and CT protocol for the diagnosis of pediatric appendicitis: reducing radiation exposure in the age of ALARA. Radiology 2011; 259:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/7\">",
"      Paulson EK, Harris JP, Jaffe TA, et al. Acute appendicitis: added diagnostic value of coronal reformations from isotropic voxels at multi-detector row CT. Radiology 2005; 235:879.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology (ACR). Acute right lower quadrant pain. ACR Appropriateness&trade; 2010 file://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonGastrointestinalImaging/RightLowerQuadrantpainDoc12.aspx (Accessed on March 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/9\">",
"      Bachur RG, Hennelly K, Callahan MJ, Monuteaux MC. Advanced radiologic imaging for pediatric appendicitis, 2005-2009: trends and outcomes. J Pediatr 2012; 160:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/10\">",
"      Vainrib M, Buklan G, Gutermacher M, et al. The impact of early sonographic evaluation on hospital admissions of children with suspected acute appendicitis. Pediatr Surg Int 2011; 27:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/11\">",
"      Sulowski C, Doria AS, Langer JC, et al. Clinical outcomes in obese and normal-weight children undergoing ultrasound for suspected appendicitis. Acad Emerg Med 2011; 18:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/12\">",
"      Dilley A, Wesson D, Munden M, et al. The impact of ultrasound examinations on the management of children with suspected appendicitis: a 3-year analysis. J Pediatr Surg 2001; 36:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/13\">",
"      Garcia Pe&ntilde;a BM, Mandl KD, Kraus SJ, et al. Ultrasonography and limited computed tomography in the diagnosis and management of appendicitis in children. JAMA 1999; 282:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/14\">",
"      Baldisserotto M, Marchiori E. Accuracy of noncompressive sonography of children with appendicitis according to the potential positions of the appendix. AJR Am J Roentgenol 2000; 175:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/15\">",
"      Lowe LH, Penney MW, Stein SM, et al. Unenhanced limited CT of the abdomen in the diagnosis of appendicitis in children: comparison with sonography. AJR Am J Roentgenol 2001; 176:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/16\">",
"      Sivit CJ, Applegate KE, Stallion A, et al. Imaging evaluation of suspected appendicitis in a pediatric population: effectiveness of sonography versus CT. AJR Am J Roentgenol 2000; 175:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/17\">",
"      Karakas SP, Guelfguat M, Leonidas JC, et al. Acute appendicitis in children: comparison of clinical diagnosis with ultrasound and CT imaging. Pediatr Radiol 2000; 30:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/18\">",
"      Goldin AB, Khanna P, Thapa M, et al. Revised ultrasound criteria for appendicitis in children improve diagnostic accuracy. Pediatr Radiol 2011; 41:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/19\">",
"      Scammell S, Lansdale N, Sprigg A, et al. Ultrasonography aids decision-making in children with abdominal pain. Ann R Coll Surg Engl 2011; 93:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/20\">",
"      Doria AS, Moineddin R, Kellenberger CJ, et al. US or CT for Diagnosis of Appendicitis in Children and Adults? A Meta-Analysis. Radiology 2006; 241:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/21\">",
"      Schuh S, Man C, Cheng A, et al. Predictors of non-diagnostic ultrasound scanning in children with suspected appendicitis. J Pediatr 2011; 158:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/22\">",
"      Lee JH, Jeong YK, Hwang JC, et al. Graded compression sonography with adjuvant use of a posterior manual compression technique in the sonographic diagnosis of acute appendicitis. AJR Am J Roentgenol 2002; 178:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/23\">",
"      Menten R, Lebecque P, Saint-Martin C, Clapuyt P. Outer diameter of the vermiform appendix: not a valid sonographic criterion for acute appendicitis in patients with cystic fibrosis. AJR Am J Roentgenol 2005; 184:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/24\">",
"      Mullins ME, Kircher MF, Ryan DP, et al. Evaluation of suspected appendicitis in children using limited helical CT and colonic contrast material. AJR Am J Roentgenol 2001; 176:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/25\">",
"      Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/26\">",
"      Klig JE. Issues of computerized tomography scans in children and implications for emergency care. Curr Opin Pediatr 2006; 18:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/27\">",
"      Brody AS, Frush DP, Huda W, et al. Radiation risk to children from computed tomography. Pediatrics 2007; 120:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/28\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/29\">",
"      Grayson DE, Wettlaufer JR, Dalrymple NC, Keesling CA. Appendiceal CT in pediatric patients: relationship of visualization to amount of peritoneal fat. AJR Am J Roentgenol 2001; 176:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/30\">",
"      Kaiser S, Finnbogason T, Jorulf HK, et al. Suspected appendicitis in children: diagnosis with contrast-enhanced versus nonenhanced Helical CT. Radiology 2004; 231:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/31\">",
"      Callahan MJ, Rodriguez DP, Taylor GA. CT of appendicitis in children. Radiology 2002; 224:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/32\">",
"      Kharbanda AB, Taylor GA, Bachur RG. Suspected appendicitis in children: rectal and intravenous contrast-enhanced versus intravenous contrast-enhanced CT. Radiology 2007; 243:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/33\">",
"      Laituri CA, Fraser JD, Aguayo P, et al. The lack of efficacy for oral contrast in the diagnosis of appendicitis by computed tomography. J Surg Res 2011; 170:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/34\">",
"      Fefferman NR, Roche KJ, Pinkney LP, et al. Suspected appendicitis in children: focused CT technique for evaluation. Radiology 2001; 220:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/35\">",
"      Donnelly LF, Emery KH, Brody AS, et al. Minimizing radiation dose for pediatric body applications of single-detector helical CT: strategies at a large Children's Hospital. AJR Am J Roentgenol 2001; 176:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/36\">",
"      Verdun FR, Lepori D, Monnin P, et al. Management of patient dose and image noise in routine pediatric CT abdominal examinations. Eur Radiol 2004; 14:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/37\">",
"      Singh S, Kalra MK, Moore MA, et al. Dose reduction and compliance with pediatric CT protocols adapted to patient size, clinical indication, and number of prior studies. Radiology 2009; 252:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/38\">",
"      Kleinman PL, Strauss KJ, Zurakowski D, et al. Patient size measured on CT images as a function of age at a tertiary care children's hospital. AJR Am J Roentgenol 2010; 194:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/39\">",
"      Frush DP. Radiation, CT, and children: the simple answer is ... it's complicated. Radiology 2009; 252:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/40\">",
"      Paterson A, Frush DP, Donnelly LF. Helical CT of the body: are settings adjusted for pediatric patients? AJR Am J Roentgenol 2001; 176:297.",
"     </a>",
"    </li>",
"    <li>",
"     file://spr.affiniscape.com/associations/5364/ig/ (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19416/abstract/42\">",
"      Campbell JP, Gunn AA. Plain abdominal radiographs and acute abdominal pain. Br J Surg 1988; 75:554.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6478 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19416=[""].join("\n");
var outline_f18_61_19416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5842759\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4189022\">",
"      CLINICAL PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4189074\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ULTRASONOGRAPHY (US)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4189194\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Posterior compression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Positional scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pitfalls and limitations of US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sonographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPUTED TOMOGRAPHY (CT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19883812\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Contrast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Focused CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - CT scanning parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pitfalls and limitations of CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CT findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22931363\">",
"      MAGNETIC RESONANCE IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PLAIN RADIOGRAPHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6478|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/50/20263\" title=\"diagnostic image 1\">",
"      Ultrasound of appendicitis child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/43/44735\" title=\"diagnostic image 2\">",
"      Appendicitis ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/42/4771\" title=\"diagnostic image 3\">",
"      Computed tomography of appendicitis in a child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/52/4930\" title=\"diagnostic image 4\">",
"      Magnetic resonance images pediatric appendicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6478|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/5/2139\" title=\"table 1\">",
"      Sonographic signs appendicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/1/3099\" title=\"table 2\">",
"      Computed tomography signs of appendicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/45/731\" title=\"table 3\">",
"      Plain film signs appendicitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31785?source=related_link\">",
"      Acute appendicitis in children: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36129?source=related_link\">",
"      Patient information: Appendicitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/37/3666?source=related_link\">",
"      Patient information: Appendicitis in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_61_19417="Short QT syndrome";
var content_f18_61_19417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Short QT syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19417/contributors\">",
"     Charles Antzelevitch, PhD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19417/contributors\">",
"     Jonathan M Cordeiro, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19417/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19417/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/61/19417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1561601136\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short QT Syndrome (SQTS) is an inherited channelopathy (disorder which affects the movement of ions through channels with the cell membrane) associated with marked shortened QT intervals and sudden cardiac death (SCD) in individuals with a structurally normal heart. In contrast to long QT syndrome, another channelopathy, ion channel defects associated with SQTS lead to abnormal abbreviation of repolarization, predisposing affected individuals to a risk of atrial and ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=see_link\">",
"     \"Pathophysiology of the long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since its first report in 2000, significant progress has been made in defining the genetic and cellular basis of SQTS as well as in therapeutic approaches to treating this syndrome. SQTS is a genetically heterogeneous disease with six different genes encoding various cardiac ion channels thus far identified. Data regarding genotype-phenotype correlation and genotype-specific treatment are promising but limited, primarily due to the lack of clinical cases.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnostic approach, and treatment modalities for SQTS will be discussed here. SCD and other channelopathies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601143\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND, INITIAL REPORT, AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1993, it was first proposed that shorter than normal QT intervals (&lt;400 msec) are associated with a 2.4-fold increased risk for SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/1\">",
"     1",
"    </a>",
"    ]. An abnormally short QT interval observed before and after runs of",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    has been reported anecdotally [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Interestingly, certain species of kangaroo, known to have a high incidence of SCD, display an abnormally short QT interval as a normal feature on their electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SQTS was first described as a clinical entity in a report of four patients with extremely short QT intervals in association with paroxysmal atrial fibrillation and SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/6\">",
"     6",
"    </a>",
"    ]. In 2003, another study further described SQTS in two unrelated European families (six patients total) with a strong family history of sudden death in association with short QT interval on ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/7\">",
"     7",
"    </a>",
"    ]. Since then, over 100 cases of SQTS have been reported, and the existence of this novel channelopathy has been validated.",
"   </p>",
"   <p>",
"    Abbreviation of the QT interval, the time elapsed between ventricular depolarization and repolarization, on the surface ECG is caused by a decrease in the action potential duration (APD) of ventricular myocytes (",
"    <a class=\"graphic graphic_figure graphicRef78354 \" href=\"UTD.htm?33/3/33852\">",
"     figure 1",
"    </a>",
"    ). The upper limit of the normal QT interval is now fairly well defined, but the lower limit of the normal QT interval and the value below which it could be considered arrhythmogenic remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The ECGs of the first few SQTS patients showed extremely short QT and QTc intervals of less than 300 msec. Since then, patients with SQTS with QT interval longer than 300 msec have been reported; however, in most cases the QT and QTc interval have been less than 360 msec. Yet the diagnosis of SQTS is complicated due to the overlapping QT range of affected individuals and apparently healthy individuals.",
"   </p>",
"   <p>",
"    To define the lower limit of the QT interval, many experts refer to a comprehensive study that investigated the distribution of normal QT interval in 14,379 healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/10\">",
"     10",
"    </a>",
"    ]. The study established the formula (Rautaharju's formula) by which the QT interval can be predicted as:",
"   </p>",
"   <p>",
"    QT predicted (QTp) =",
"    <span class=\"nowrap\">",
"     656/(1+",
"    </span>",
"    heart",
"    <span class=\"nowrap\">",
"     rate/100)",
"    </span>",
"   </p>",
"   <p>",
"    The prevalence of QT interval shorter than 88 percent of QTp",
"    <span class=\"nowrap\">",
"     (QT/QTp",
"    </span>",
"    &lt;88 percent, which is equivalent to two standard deviations below the mean) was 0.03 percent. Based on this observation, it was suggested that QT intervals less than 88 percent of QTp (two standard deviations below mean predicted value) at a particular heart rate may be considered as short QT intervals. For example, at a heart rate of 60 beats per minute (bpm), per Rautaharju's formula, QTp would be 410 msec. Eighty-eight percent of QTp (410 msec) would be 360 msec. QT interval values less than 80 percent of QTp may be considered extremely short (which is equivalent 320 msec at heart rate of 60) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical experience clearly indicates that the vast majority of patients with QTc values in the 330 to 360 range are not at risk, although a select few may be. (See",
"    <a class=\"local\" href=\"#H341687\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5697920\">",
"    <span class=\"h1\">",
"     PREVALENCE OF A SHORT QT INTERVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the epidemiologic data available for many other electrocardiogram (ECG) parameters, including long QT intervals, the precise prevalence of a short QT interval in the general population is unknown but appears to be 2 percent or less when using a cutoff of 360 msec. This is largely the case due to the long-standing failure to identify any risk associated with shorter-than-normal QT intervals as well as the varying definitions of what constitutes a shorter-than-normal QT interval.",
"   </p>",
"   <p>",
"    Several large cohorts have attempted to identify the frequency of short QT interval in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. The precise definition of a short QT has varied slightly in each of the cohorts, but in all of the studies, patients classified as having a short QT interval had a rate-corrected QTc of 369 msec or less. The prevalence was estimated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Finnish cohort of 10,822 middle-aged (mean 44 years) patients, 0.4 percent had a short QT interval (&lt;340 msec), and 0.1 percent had a very short QT interval (&lt;320 msec) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Swiss cohort of 41,767 army conscripts (99.6 percent male, mean age 19 years), 1 percent had a short QT interval (&lt;347 msec), and 0.02 percent had a very short QT interval (&lt;320 msec) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an American cohort of 46,129 healthy volunteers (53 percent female), 2 percent had a QT interval &le;360 msec [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Japanese cohort of 114,334 patients with ECGs stored in an electronic database, 0.4 percent were found to have short QT intervals (&le;362 msec in males, &le;369 msec in females) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601157\">",
"    <span class=\"h1\">",
"     GENETIC BASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SQTS is a genetically heterogeneous disease with mutations in six different genes (three gain of function and three loss of function) that encode different cardiac ion channels having been identified and termed SQT1 to SQT6 based on the chronology of their discovery (",
"    <a class=\"graphic graphic_table graphicRef72304 \" href=\"UTD.htm?32/60/33740\">",
"     table 1",
"    </a>",
"    ). SQT1 and SQT3-6 have been reported in familial setting, and SQT2 is reported only in a single patient in a sporadic setting. SQTS traits are transmitted in an autosomal dominant fashion. Many of the genes involved in SQTS are the same as those responsible for LQTS; however, the net effect of the mutations in SQTS is to increase repolarizing forces, an effect opposite to that encountered in LQTS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetics of congenital and acquired long QT syndrome\", section on 'Types of congenital LQTS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest available case series of SQTS describes the clinical presentation of 29 patients with SQTS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/19\">",
"     19",
"    </a>",
"    ]. The most common form of SQTS (SQT1) was linked to mutations in KCNH2, the gene encoding the &alpha;-subunit of the rapid delayed rectifier K",
"    <sup>",
"     +",
"    </sup>",
"    channel (I",
"    <sub>",
"     Kr",
"    </sub>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef70771 \" href=\"UTD.htm?19/59/20401\">",
"     figure 2",
"    </a>",
"    ). Approximately 25 percent of patients had a mutation in",
"    <em>",
"     KCNH2",
"    </em>",
"    , and no mutation was found in the rest of the patients. Mutations in",
"    <em>",
"     KCNQ1",
"    </em>",
"    and",
"    <em>",
"     KCNJ2",
"    </em>",
"    were not detected, and",
"    <em>",
"     CACNA1c",
"    </em>",
"    and",
"    <em>",
"     CACNB2b",
"    </em>",
"    were not screened.",
"   </p>",
"   <p>",
"    The N588K mutation in",
"    <em>",
"     KCNH2",
"    </em>",
"    was first identified in three separate families with shorter than normal QT intervals and a high incidence of ventricular arrhythmias and sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. Patch clamp analysis of N588K revealed this mutation completely removed inactivation over a physiological range of potentials, resulting in a dramatic increase in I",
"    <sub>",
"     Kr",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A second mutation at T618I in",
"    <em>",
"     KCNH2",
"    </em>",
"    has been discovered and linked to SQT1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/23\">",
"     23",
"    </a>",
"    ]. Interestingly, a novel mutation, R1135H in",
"    <em>",
"     KCNH2",
"    </em>",
"    , has been identified in a patient with short QT interval as well as a Brugada-type ECG, suggesting that SQTS may also present with other channelopathies.",
"   </p>",
"   <p>",
"    Indeed, many SQTS patients carrying mutations in the L-type calcium channel genes (",
"    <em>",
"     CACNA1C, CACNB2",
"    </em>",
"    and",
"    <em>",
"     CACNA2D1",
"    </em>",
"    ) manifest an ST segment elevation on the surface electrocardiogram in addition to a shorter than normal QT interval and appear to have a combined",
"    <span class=\"nowrap\">",
"     Brugada/Short",
"    </span>",
"    QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Most patients harboring a calcium channel mutation who display normal QT intervals have been shown to carry secondary genetic variations that are known to prolong the QT interval. QT-prolonging variations (p.D601E-",
"    <em>",
"     CACNB2b,",
"    </em>",
"    p.K897T-",
"    <em>",
"     KNCH2,",
"    </em>",
"    p.T10M-",
"    <em>",
"     KCNE2,",
"    </em>",
"    p.R1047L",
"    <em>",
"     -KCNH2,",
"    </em>",
"    p.D76N",
"    <em>",
"     -KCNE1,",
"    </em>",
"    p.G643S",
"    <em>",
"     -KCNQ1)",
"    </em>",
"    were found in 12 of the 14 BrS probands presenting with a normal QTc [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175416\">",
"    <span class=\"h1\">",
"     CELLULAR BASIS OF ARRHYTHMOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QT interval is determined by the ventricular action potential duration, which in turn is dependent upon a delicate balance of currents active during the repolarization phase of the action potential (",
"    <a class=\"graphic graphic_figure graphicRef78354 \" href=\"UTD.htm?33/3/33852\">",
"     figure 1",
"    </a>",
"    ). An increase in net outward current due to either a reduction in inward depolarizing currents like I",
"    <sub>",
"     Ca",
"    </sub>",
"    (SQT4- SQT6) or augmentation of outward repolarizing currents such as I",
"    <sub>",
"     Kr",
"    </sub>",
"    (SQT1), I",
"    <sub>",
"     Ks",
"    </sub>",
"    (SQT2) I",
"    <sub>",
"     K1",
"    </sub>",
"    (SQT3), or a combination thereof, can shift the balance of current favoring early repolarization, thus leading to abbreviation of action potential duration, refractoriness, and QT interval (",
"    <a class=\"graphic graphic_figure graphicRef70771 \" href=\"UTD.htm?19/59/20401\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Available data suggest that abbreviation of the action potential in SQTS is heterogeneous with preferential abbreviation of either epicardial or endocardial cells as compared with sub-endocardial M cells, resulting in tall, positive T waves on the ECG and an increase in transmural dispersion of repolarization (TDR) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Dispersion of repolarization serves as substrate, and abbreviation of wavelength (product of refractory period and conduction velocity) promotes the initiation and maintenance of reentry under conditions of SQTS.",
"   </p>",
"   <p>",
"    The trigger responsible for generating the premature beat that precipitates polymorphic ventricular tachycardia (VT) in SQTS is not known but may involve a phase 2 reentry or late phase 3 early afterdepolarization mechanism, which may give rise to R-on-T extrasystoles [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Alternatively, re-excitation of the ventricles from the Purkinje fiber network may initiate the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/21,30\">",
"     21,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the experimental setting, shortening of the action potential duration (and thus QT interval) results in a reduction in contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, reports have shown that while electrical repolarization in SQTS patient is abbreviated, mechanical contraction is not, suggesting an electromechanical dissociation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A gain-of-function mutation augments outward potassium current in SQT1-3, and a loss-of-function mutation reduces I",
"    <sub>",
"     Ca",
"    </sub>",
"    in SQT4-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/20,24,25,34,35\">",
"     20,24,25,34,35",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     T",
"     <sub>",
"      peak",
"     </sub>",
"     -T",
"     <sub>",
"      end",
"     </sub>",
"     /QT",
"    </span>",
"    ratio, an electrocardiographic index of spatial dispersion of repolarization, is significantly augmented in most cases of SQTS, suggesting an increase in TDR at the cellular level [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Interestingly, this ratio is more amplified in patients who are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/38\">",
"     38",
"    </a>",
"    ]. The increase in TDR is known to predispose to phase 2 reentry and may be responsible for the closely-coupled premature ventricular extrasystole that precedes the onset of polymorphic VT in SQTS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601164\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of SQTS is variable, and many patients are asymptomatic. The initial presentation and subsequent clinical course of SQTS varies among different families and even within different members of the same family, as shown in the following case series of 29 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first manifestation of the disease was reported at an age as young as one month or as old as 80 years.",
"     </li>",
"     <li>",
"      62 percent of the patients (18 out of 29) were symptomatic. The most frequently reported symptoms were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cardiac arrest &mdash; 34 percent (this was the initial symptom in 28 percent)",
"     </li>",
"     <li>",
"      Palpitations &mdash; 31 percent",
"     </li>",
"     <li>",
"      Syncope &mdash; 24 percent",
"     </li>",
"     <li>",
"      Atrial fibrillation &mdash; 17 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      38 percent of the patients (11 out of 29) were asymptomatic and were diagnosed based on a strong family history of arrhythmic symptoms including SCD, a common finding in familial forms of SQTS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The circumstances surrounding the onset of symptoms are highly variable, and episodes of sudden cardiac death (SCD) have been reported at rest, following a loud noise, during exercises, and during routine daily activities. SCD occurred in the first month of life in two patients, suggesting that SQTS may contribute to sudden infant death syndrome (SIDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted in a report of 53 patients from the European Short QT Registry (75 percent males; median age 26 years) who were followed for up to 64 &plusmn; 27 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A familial or personal history of cardiac arrest was present in 89 percent.",
"     </li>",
"     <li>",
"      Sudden death was the clinical presentation in 32 percent.",
"     </li>",
"     <li>",
"      The average QTc was 314 &plusmn; 23 msec.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic patients were found to have a high risk of recurrent arrhythmic events, with a high risk of sudden death in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H339863\">",
"    <span class=\"h2\">",
"     Initial presentation by SQTS subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation of SQTS is variable depending on the underlying genetic mutation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SQT1 was initially reported in two families with hereditary short QT syndrome and a high incidence of ventricular arrhythmias and sudden cardiac death (SCD) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SQT2 has only been reported in a single patient, a 70-year-old male who was successfully resuscitated after an episode of ventricular fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SQT3 was first reported in a family with two afflicted members [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/35\">",
"       35",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An asymptomatic five-year-old girl presented with a QTc of 315 msec, with the T wave noticeably narrow and peaked.",
"     </li>",
"     <li>",
"      The 35-year-old father presented a QTc of 320 msec and had a history of presyncopal events and palpitations since age 15.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SQT4 has thus far been reported in two different patients from unrelated families [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/25\">",
"       25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A 41-year-old male with a family history of SCD who presented with atrial fibrillation and a QTc of 346 msec.",
"     </li>",
"     <li>",
"      A 44-year-old male with a family history of syncope and SCD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SQT5 has been described in seven patients belonging to a family of European descent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/25\">",
"       25",
"      </a>",
"      ]. The proband, a 25-year-old male, presented with a QTc of 330 msec and had an episode of aborted SCD. His 23-year-old brother had frequent syncope as well.",
"     </li>",
"     <li>",
"      SQT6 has been reported in an otherwise healthy 17-year-old female who had SCD with an initial rhythm of ventricular fibrillation while sitting during a church service. Subsequently the ECG had a QTc of 329 msec with tall, narrow, and symmetrical T waves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601171\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any survivor of sudden cardiac death (SCD), a history and physical examination focusing on potential underlying etiologies of SCD (eg, myocardial ischemia, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, intoxications) should be performed. Paroxysmal atrial fibrillation is very common in patients with SQTS; thus, diagnosis of SQTS should be considered in young individuals with lone atrial fibrillation with shorter than normal QT intervals. A history of arrhythmic symptoms, family history of lone atrial fibrillation, or primary or resuscitated ventricular fibrillation or SCD may provide additional clues. The isolated presence of short QT interval without associated arrhythmogenic complication warrants further interrogation to rule out SQTS.",
"   </p>",
"   <p>",
"    Patients in whom SQTS is suspected should all undergo a routine surface electrocardiogram (ECG) at the time of presentation. Our approach to additional testing, which may include exercise stress testing, invasive electrophysiology studies, echocardiography, 24-hour ambulatory monitoring, and cardiac magnetic resonance imaging, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341508\">",
"    <span class=\"h2\">",
"     Electrocardiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical ECG findings associated with SQTS include the following (",
"    <a class=\"graphic graphic_waveform graphicRef51616 \" href=\"UTD.htm?38/15/39158\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/6,7,19,42\">",
"     6,7,19,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormally short QT interval, usually &lt;360 msec with a range of 220 to 360 msec",
"     </li>",
"     <li>",
"      Absence of ST segment",
"     </li>",
"     <li>",
"      Tall and peaked T waves in the precordial leads, which can be positive or negative, symmetrical or asymmetrical",
"     </li>",
"     <li>",
"      Poor rate adaptation of QT interval (diminished rate dependence) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolonged T",
"      <sub>",
"       peak",
"      </sub>",
"      -T",
"      <sub>",
"       end",
"      </sub>",
"      interval and",
"      <span class=\"nowrap\">",
"       T",
"       <sub>",
"        peak",
"       </sub>",
"       -T",
"       <sub>",
"        end",
"       </sub>",
"       /QT",
"      </span>",
"      ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with SQTS have QTc &lt;340 msec with a range of 210 to 320 msec. However, in patients with SQT4 and SQT5, QTc intervals are slightly longer (340 to 360 msec). No correlation thus far has been identified between the magnitude of QT interval abbreviation and the risk of arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cases of SQT4, 5, and 6, short QT intervals may appear together with a Brugada type ST segment elevation in the right precordial leads V1-V3 at baseline or after administration of a potent sodium channel blocker (",
"    <a class=\"graphic graphic_waveform graphicRef51616 \" href=\"UTD.htm?38/15/39158\">",
"     waveform 1",
"    </a>",
"    ) or other unmasking agent, such as a potassium channel opener (I",
"    <sub>",
"     KATP",
"    </sub>",
"    activator) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/25\">",
"     25",
"    </a>",
"    ]. Approximately 65 percent of patients with SQTS have ECG features of early repolarization, characterized by J-point elevation in the inferolateral leads, which may also be associated with an increased likelihood of increased arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link&amp;anchor=H2#H2\">",
"     \"Brugada syndrome\", section on 'ECG patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the diagnosis of SQTS is suspected, a resting 12-lead ECG should be performed at a heart rate within normal limits, preferably less than 80 beats per minutes. In patients with SQTS, the QT interval fails to lengthen appropriately with a decrease in the heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/43\">",
"     43",
"    </a>",
"    ]. As a consequence, QT correction using Bazzett's or comparable formulas (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?7/48/7937?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) will overcorrect at initially fast rates, leading to a false negative diagnosis. Overnight Holter monitoring or long-term ECG monitoring may prove helpful in such cases as this allows for analysis of the QT interval during periods of slower heart rate (ie, sleep) and also allows for patient-specific QT correction for heart rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37687?source=see_link&amp;anchor=H9#H9\">",
"     \"ECG tutorial: Basic principles of ECG analysis\", section on 'QT interval'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While data are relatively sparse, owing to the rarity of the syndrome, the picture that appears to be developing is that SQT1 and 2 probands generally manifest symmetrical tall peaked T waves, whereas SQT3 probands display asymmetrical tall peaked T waves with a more rapidly descending than ascending limb of the T wave [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/35\">",
"     35",
"    </a>",
"    ]. SQT3, 4, 5, and 6 show variable T wave heights but are usually symmetrical. In most cases, a distinct ST segment is short or absent, with the T wave originating from the S wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601193\">",
"    <span class=\"h2\">",
"     Electrophysiological study",
"    </span>",
"    &nbsp;&mdash;&nbsp;During invasive electrophysiological studies (EPS), SQTS patients characteristically show extremely short atrial and ventricular effective refractory periods (ERP), regardless of genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/7,19,25,34,35\">",
"     7,19,25,34,35",
"    </a>",
"    ]. The ventricular ERP measured at the right ventricular apex varies between 140 and 180 msec at a cycle length of 500 to 600 msec and 130 to 180 msec at pacing cycle length of 400 to 430 msec. Atrial ERP measured in the high lateral right atrium varies between 120 and 180 msec at a cycle length of 600 msec. The programmed electrical stimulation with two to three premature stimuli down to refractoriness induced both atrial fibrillation and ventricular fibrillation (VF) in many patients. The inducibility of VF at EPS in SQTS patients is about 60 percent. Moreover, in one case series, VF was inducible at EPS in only three of six patient with clinically documented VF, suggesting that the sensitivity of EP study for the inducibility of VF is low [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/19\">",
"     19",
"    </a>",
"    ]. Although EPS has a role in confirming the diagnosis by revealing short ventricular refractory periods, its role in risk stratification remains unclear. As such, we do not routinely perform EPS unless the diagnosis of short QT syndrome remains unclear based on the available ECG data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=see_link\">",
"     \"Overview of invasive cardiac electrophysiology studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175129\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients where SQTS is suspected as the diagnosis, based on ECG findings and clinical history, genetic testing of the patient and immediate relatives should be considered. Given the relative scarcity of this clinical entity, decisions regarding genotyping should be performed in collaboration with an electrophysiologist or other clinician with expertise in the evaluation and diagnosis of patients with suspected SQTS. (See",
"    <a class=\"local\" href=\"#H1561601157\">",
"     'Genetic basis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3739469511\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3739469511\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;While ECG findings in SQTS can be suggestive of the diagnosis, the solitary presence of a shorter than normal QT interval does not appear to be diagnostic. Clinical history, family history of sudden death, and genotype results all contribute to the diagnostic certainty.",
"   </p>",
"   <p>",
"    Based on a comprehensive review of 61 reported cases of the SQTS, proposed diagnostic criteria were developed to facilitate the evaluation of individuals suspected to have SQTS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/9\">",
"     9",
"    </a>",
"    ]. A scoring system was developed based on ECG characteristics, clinical presentation, family history, and genetic findings (",
"    <a class=\"graphic graphic_table graphicRef65743 \" href=\"UTD.htm?33/14/34028\">",
"     table 2",
"    </a>",
"    ). The most controversial aspect of the differential diagnosis of SQTS involves the QT interval cutoff, as shown by the increasing number of points assigned to shorter QT intervals in the proposed diagnostic criteria.",
"   </p>",
"   <p>",
"    The authors and editors of this topic agree with and recommend following the proposed diagnostic criteria for SQTS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3633016551\">",
"    <span class=\"h2\">",
"     Screening family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-degree relatives of those diagnosed with SQTS should undergo clinical screening with an electrocardiogram (ECG) and genetic testing. Mutation-specific genetic testing is recommended",
"    <strong>",
"    </strong>",
"    for all family members and relatives suspected of SQTS following the identification of the SQTS-causative mutation in an index case [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/46\">",
"     46",
"    </a>",
"    ]. Family members who test positive for the familial mutation should consult a cardiologist with expertise in SQTS to discuss further management.&nbsp;Conversely, a negative genetic test for the familial mutation obviates the need for repeated follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341687\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before arriving at a diagnosis of SQTS, other potential causes for QT shortening should be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616552\">",
"    <span class=\"h2\">",
"     Normal variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sole presence of a shorter-than-normal QT interval does not appear to be diagnostic for SQTS and, in fact, may represent a normal variant in many people. Up to 2 percent of the population have QT intervals &le; 360 msec, highlighting the importance of utilizing the diagnostic criteria for the diagnosis of SQTS. (See",
"    <a class=\"local\" href=\"#H5697920\">",
"     'Prevalence of a short QT interval'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3739469511\">",
"     'Diagnostic criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175259\">",
"    <span class=\"h2\">",
"     Acquired causes of short QT interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary causes of short QT interval such as hyperkalemia, acidosis, hypercalcemia, hyperthermia, effect of drugs like digitalis, effect of acetylcholine or catecholamine, and abbreviation of QT interval related to activation of ATP-sensitive K",
"    <sup>",
"     +",
"    </sup>",
"    current (I",
"    <sub>",
"     KATP",
"    </sub>",
"    ) need to be ruled out (",
"    <a class=\"graphic graphic_table graphicRef59159 \" href=\"UTD.htm?5/35/5691\">",
"     table 3",
"    </a>",
"    ). As with cases of QT prolongation, QT interval shortening may be caused by a combination of genetic and secondary causes, including hyperkalemia, hypercalcemia, acidosis, myocardial ischemia, and increased vagal tone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175234\">",
"    <span class=\"h2\">",
"     Deceleration-dependent shortening of the QT interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare but interesting paradoxical ECG phenomenon called deceleration-dependent shortening of QT interval (DDSQTI) should also be considered in the differential diagnosis of SQTS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/6\">",
"     6",
"    </a>",
"    ]. Strong parasympathetic stimulation can lead to bradycardia and concurrent activation of myocardial acetylcholine-sensitive K",
"    <sup>",
"     +",
"    </sup>",
"    channels (K",
"    <sub>",
"     Ach",
"    </sub>",
"    ). In such cases, the QT interval abbreviates paradoxically with a decrease in heart rate instead of lengthening. Such shortening of the QT interval may be transient and should resolve as parasympathetic tone decreases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601207\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PATIENTS WITH A SHORT QT INTERVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, the sole presence of a shorter-than-normal QT interval on an electrocardiogram (ECG) does not appear to be diagnostic for the short QT syndrome and, in isolation, may not be associated with an increased risk of sudden cardiac death (SCD). Because the rate of serious complications of ICD therapy is not trivial, particularly over the life of a young patient, it is important to discriminate between patients with an isolated short QT interval and those who meet the criteria for SQTS (",
"    <a class=\"graphic graphic_table graphicRef65743 \" href=\"UTD.htm?33/14/34028\">",
"     table 2",
"    </a>",
"    ). Prior to making a final decision regarding the management of these patients, acquired causes of a shortened QT interval should be excluded. (See",
"    <a class=\"local\" href=\"#H175259\">",
"     'Acquired causes of short QT interval'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3288843\">",
"    <span class=\"h2\">",
"     Patients with an isolated short QT interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials and few observational studies of patients assessing the prognosis of patients with isolated short QT intervals who have no apparent clinical history, family history, or genetic criteria suggestive of SQTS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/47\">",
"     47",
"    </a>",
"    ]. As such, the following management strategies for such patients are based on expert opinion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a short QT interval only (330 msec or greater) who have none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS are classified as low-probability for the diagnosis of SQTS. For these low-probability patients, we suggest no specific pharmacologic or device-based therapy.",
"     </li>",
"     <li>",
"      Patients with a markedly shortened QT interval only (&lt;330 msec) are classified as intermediate-probability for the diagnosis of SQTS despite having none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS. For these intermediate-probability patients, we suggest no specific pharmacologic or device-based therapy. We do suggest referral to an electrophysiologist for comprehensive testing, including genetic screening, if this has not yet been completed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3288858\">",
"    <span class=\"h2\">",
"     Patients with a short QT interval who have a high probability of SQTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with a QT interval &lt;350 msec and at least one criteria from the list of clinical history, family history, or genotype criteria will be classified as high-probability for the SQTS. Because of the association between SQTS and sudden cardiac death due to arrhythmias, therapy with an implantable cardioverter-defibrillator (ICD) is recommended in these patients, along with consideration of antiarrhythmic therapy if appropriate shocks are frequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601214\">",
"    <span class=\"h3\">",
"     Implantable cardioverter-defibrillator (ICD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SQTS are at a very high risk for sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/14\">",
"     14",
"    </a>",
"    ]. As such, we recommend ICD implantation for both primary and secondary prevention of SCD in patients with SQTS unless absolutely contraindicated or refused by the patient. Because the sensitivity of inducibility of ventricular fibrillation (VF) is only 50 percent, failure to induce VF during EP study does not preclude future risk of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/19,40\">",
"     19,40",
"    </a>",
"    ]. Accordingly, a negative EP study should not defer a clinician's decision to implant an ICD.",
"   </p>",
"   <p>",
"    Oversensing of the T wave is a frequent clinical problem encountered in patients with SQTS who receive an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/48\">",
"     48",
"    </a>",
"    ]. The tall, peaked, and closely coupled T waves are often mistakenly sensed as R waves, leading to inappropriate ICD shocks. Reprogramming the decay delay, the sensitivity, or both generally prevents such inappropriate discharges. Caution must be exercised to avoid programming modifications that prevent the detection of lethal ventricular tachyarrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601230\">",
"    <span class=\"h3\">",
"     Pharmacological therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacological therapy is primarily used as an adjunct to ICD placement. However, pharmacologic therapy may be the primary treatment modality in patients who refuse ICD placement, patients with an absolute contraindication to ICD placement, or in very young patients in whom ICD implantation is problematic. For patients with SQTS who have refused or are not candidates for ICD therapy, or in those with recurrent ventricular arrhythmias resulting in frequent ICD therapy, we recommend adjunctive pharmacological therapy with QT prolonging drugs. In the case of SQT1, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    rather than a class IC or class III (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 4",
"    </a>",
"    ) antiarrhythmic drug. In other forms of SQTS, data are too limited to permit specific suggestions or recommendations.",
"   </p>",
"   <p>",
"    Data regarding pharmacological therapy in SQTS are very limited, with much of the data pertaining to patients with SQT1:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four different antiarrhythmic drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"       ibutilide",
"      </a>",
"      , and hydroquinidine, were tested in six patients with SQT1 to determine their effects on various electrophysiologic properties [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/49\">",
"       49",
"      </a>",
"      ]. Only hydroquinidine, a class IA antiarrhythmic drug (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 4",
"      </a>",
"      ), normalized the QT interval, increased ventricular ERP, and rendered ventricular fibrillation noninducible. In a one-year follow-up, patients treated with hydroquinidine remained asymptomatic, and no further episodes of ventricular arrhythmia were detected [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      has proved to be effective in prolonging the QT interval and restoring the ventricular effective refractory period towards normal [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/50\">",
"       50",
"      </a>",
"      ]. The combination of disopyramide and nifekalant, a class III agent available primarily in Japan, was reported in one patient to increase QTc to &gt;410 msec [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      has been shown to prolong the QT interval in two patients with SQTS of unknown genotype [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The failure of class IC and pure class III antiarrhythmic drugs in SQT1 caused by the N588K mutation in KCNH2 is due to the fact that this mutation results in a desensitization of the channel to these agents. Class III agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , E-4031, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    have a greater affinity for the inactivated state of the channel.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     Quinidine",
"    </a>",
"    , by virtue of its effect to block the activated state of the I",
"    <sub>",
"     Kr",
"    </sub>",
"    channel, was reasoned to be more effective in this setting in which the inactivated state of the channel is lost.",
"   </p>",
"   <p>",
"    It is thought that the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    in SQT1 is due to its ability to inhibit the N588K channel at pharmacologically relevant concentrations, presumably due not only to its ability to block the activated state of the I",
"    <sub>",
"     Kr",
"    </sub>",
"    channel, but also its ability to block other outward currents, particularly I",
"    <sub>",
"     Ks.",
"    </sub>",
"    Quinidine's multi-ion channel inhibition may underlie its effectiveness in other forms of SQTS, particularly SQT4-SQT6 where its I",
"    <sub>",
"     to",
"    </sub>",
"    blocking action may provide a therapeutic edge over other antiarrhythmic drugs by reducing the substrate and trigger for Brugada syndrome. Prolongation of the QT interval by quinidine has been reported in one patient with SQT4 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial fibrillation (AF) is another common clinical problem in SQTS. Some patient with SQTS exhibit only AF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/52\">",
"     52",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"     Propafenone",
"    </a>",
"    as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    have been shown to be therapeutically effective is a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19417/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1561601237\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short QT Syndrome (SQTS) is an inherited channelopathy (disorder which affects the movement of ions through channels with the cell membrane) associated with marked shortening of QT intervals and sudden cardiac death (SCD) in individuals with structurally normal hearts. (See",
"      <a class=\"local\" href=\"#H1561601136\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SQTS is a genetically heterogeneous disease, with mutations in six different genes (three gain of function and three loss of function) that encode different cardiac ion channels having been identified and termed SQT1 to SQT6 based on the chronology of their discovery (",
"      <a class=\"graphic graphic_table graphicRef72304 \" href=\"UTD.htm?32/60/33740\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1561601157\">",
"       'Genetic basis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of SQTS is variable, and while many patients are asymptomatic, the majority present with one or more of the following: SCD, palpitations, syncope, and atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H1561601164\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical electrocardiogram (ECG) findings associated with SQTS include an abnormally short QT interval (usually &lt;360 msec with a range of 220 to 360 msec), absence of the ST segment, tall and peaked T waves in the precordial leads, and poor rate adaptation of the QT interval. (See",
"      <a class=\"local\" href=\"#H341508\">",
"       'Electrocardiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sole presence of a shorter-than-normal QT interval does not appear to be diagnostic for SQTS and may represent a normal variant in many people in up to 2 percent of the population. Diagnostic criteria have been developed to facilitate the evaluation of individuals suspected to have SQTS, with a scoring system based on ECG characteristics, clinical presentation, family history, and genetic findings (",
"      <a class=\"graphic graphic_table graphicRef65743 \" href=\"UTD.htm?33/14/34028\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3739469511\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-degree relatives of those diagnosed with SQTS should undergo clinical screening with an electrocardiogram (ECG) and genetic testing. Mutation-specific genetic testing is recommended",
"      <strong>",
"      </strong>",
"      for all family members and relatives suspected of SQTS following the identification of the SQTS-causative mutation in an index case. Family members who test positive for the familial mutation should be seen by a cardiologist with expertise in SQTS to discuss further management. (See",
"      <a class=\"local\" href=\"#H3633016551\">",
"       'Screening family members'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before arriving at a diagnosis of SQTS, other potential causes for QT shortening should be excluded, including hyperkalemia, acidosis, hypercalcemia, hyperthermia, effect of drugs like digitalis, increased vagal tone, and deceleration-dependent shortening of QT interval. (See",
"      <a class=\"local\" href=\"#H341687\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with a shortened QT interval varies depending on whether the short QT interval occurs in isolation or is associated with other clinical history, family history, or genetic criteria (",
"      <a class=\"graphic graphic_table graphicRef65743 \" href=\"UTD.htm?33/14/34028\">",
"       table 2",
"      </a>",
"      ) that increase the probability of SQTS. As discussed previously, the sole presence of a shorter-than-normal QT interval on an electrocardiogram (ECG) does not appear to be diagnostic for the SQTS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with a short QT interval only (330 msec or greater) who have none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS are classified as low-probability for the diagnosis of SQTS. For these low-probability patients, we suggest no specific pharmacologic or device-based therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with a markedly shortened QT interval only (&lt;330 msec) are classified as intermediate-probability for the diagnosis of SQTS, despite having none of the clinical history, family history, or genotype criteria proposed for the diagnosis of SQTS. For these intermediate-probability patients, we suggest no specific pharmacologic or device-based therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We do suggest referral to an electrophysiologist for comprehensive testing, including genetic screening, if this has not yet been completed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with SQTS are at a very high risk for sudden cardiac death (SCD). As such, we recommend implantable cardioverter-defibrillator (ICD) implantation for both primary and secondary prevention of SCD unless absolutely contraindicated or refused by the patient (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1561601214\">",
"       'Implantable cardioverter-defibrillator (ICD)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While pharmacological therapy in patients with SQTS is primarily used as an adjunct to ICD placement, it may be the primary treatment modality in patients who refuse ICD placement, patients with an absolute contraindication to ICD placement, or in very young patients in whom ICD implantation is problematic. For patients with SQTS who have refused or are not candidates for ICD therapy, or in those with recurrent ventricular arrhythmias resulting in frequent ICD therapy, we recommend adjunctive pharmacological therapy with a QT prolonging drug. In the case of SQT1, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      rather than a class IC or class III (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 4",
"      </a>",
"      ) antiarrhythmic drug (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This recommendation is based on the positive electrophysiologic effects of quinidine (eg, QT prolongation to the normal range) in patients with SQTS studied thus far. (See",
"      <a class=\"local\" href=\"#H1561601230\">",
"       'Pharmacological therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/1\">",
"      Algra A, Tijssen JG, Roelandt JR, et al. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J 1993; 70:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/2\">",
"      Fei L, Camm AJ. Shortening of the QT interval immediately preceding the onset of idiopathic spontaneous ventricular tachycardia. Am Heart J 1995; 130:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/3\">",
"      Kontny F, Dale J. Self-terminating idiopathic ventricular fibrillation presenting as syncope: a 40-year follow-up report. J Intern Med 1990; 227:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/4\">",
"      Campbell TJ. Characteristics of cardiac action potentials in marsupials. J Comp Physiol B 1989; 158:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/5\">",
"      Rezakhani A, Webster JD, Atwell RB. The electrocardiogram of the eastern grey kangaroo (Macropus giganteus). Aust Vet J 1986; 63:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/6\">",
"      Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000; 94:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/7\">",
"      Gaita F, Giustetto C, Bianchi F, et al. Short QT Syndrome: a familial cause of sudden death. Circulation 2003; 108:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/8\">",
"      Cross B, Homoud M, Link M, et al. The short QT syndrome. J Interv Card Electrophysiol 2011; 31:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/9\">",
"      Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol 2011; 57:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/10\">",
"      Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8:690.",
"     </a>",
"    </li>",
"    <li>",
"     Gussak I, Antzelevitch C, Goodman D, Bjerregaard P. Short QT interval: ECG phenomenon and clinical syndrome. In: Cardiac Repolarization. Bridging Basic and Clinical Sciences, Gussak I, Antzelevitch C (Eds), Humana Press, Totowa, NJ 2003. p.497.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/12\">",
"      Gussak I, Bjerregaard P. Short QT syndrome--5 years of progress. J Electrocardiol 2005; 38:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/13\">",
"      Bjerregaard P, Gussak I. Short QT syndrome. Ann Noninvasive Electrocardiol 2005; 10:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/14\">",
"      Bjerregaard P, Gussak I. Short QT syndrome: mechanisms, diagnosis and treatment. Nat Clin Pract Cardiovasc Med 2005; 2:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/15\">",
"      Anttonen O, Junttila MJ, Rissanen H, et al. Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. Circulation 2007; 116:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/16\">",
"      Kobza R, Roos M, Niggli B, et al. Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts. Heart Rhythm 2009; 6:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/17\">",
"      Miyamoto A, Hayashi H, Yoshino T, et al. Clinical and electrocardiographic characteristics of patients with short QT interval in a large hospital-based population. Heart Rhythm 2012; 9:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/18\">",
"      Mason JW, Ramseth DJ, Chanter DO, et al. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol 2007; 40:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/19\">",
"      Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006; 27:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/20\">",
"      Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/21\">",
"      Cordeiro JM, Brugada R, Wu YS, et al. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res 2005; 67:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/22\">",
"      McPate MJ, Duncan RS, Milnes JT, et al. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C. Biochem Biophys Res Commun 2005; 334:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/23\">",
"      Sun Y, Quan XQ, Fromme S, et al. A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol 2011; 50:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/24\">",
"      Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011; 32:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/25\">",
"      Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/26\">",
"      Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010; 7:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/27\">",
"      Patel C, Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 2008; 5:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/28\">",
"      Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004; 110:3661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/29\">",
"      Burashnikov A, Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol 2006; 29:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/30\">",
"      McPate MJ, Zhang H, Adeniran I, et al. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study. J Physiol Pharmacol 2009; 60:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/31\">",
"      Cordeiro JM, Greene L, Heilmann C, et al. Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol 2004; 286:H1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/32\">",
"      Sah R, Ramirez RJ, Oudit GY, et al. Regulation of cardiac excitation-contraction coupling by action potential repolarization: role of the transient outward potassium current (I(to)). J Physiol 2003; 546:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/33\">",
"      Schimpf R, Antzelevitch C, Haghi D, et al. Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm 2008; 5:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/34\">",
"      Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/35\">",
"      Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005; 96:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/36\">",
"      Anttonen O, V&auml;&auml;n&auml;nen H, Junttila J, et al. Electrocardiographic transmural dispersion of repolarization in patients with inherited short QT syndrome. Ann Noninvasive Electrocardiol 2008; 13:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/37\">",
"      Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008; 41:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/38\">",
"      Anttonen O, Junttila MJ, Maury P, et al. Differences in twelve-lead electrocardiogram between symptomatic and asymptomatic subjects with short QT interval. Heart Rhythm 2009; 6:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/39\">",
"      Lu LX, Zhou W, Zhang X, et al. Short QT syndrome: a case report and review of literature. Resuscitation 2006; 71:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/40\">",
"      Schimpf R, Bauersfeld U, Gaita F, Wolpert C. Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. Heart Rhythm 2005; 2:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/41\">",
"      Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011; 58:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/42\">",
"      Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol 2010; 3:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/43\">",
"      Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 2005; 16:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/44\">",
"      Watanabe H, Makiyama T, Koyama T, et al. High prevalence of early repolarization in short QT syndrome. Heart Rhythm 2010; 7:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/45\">",
"      Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm 2010; 7:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/46\">",
"      Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/47\">",
"      Zhang Y, Post WS, Dalal D, et al. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2011; 171:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/48\">",
"      Schimpf R, Wolpert C, Bianchi F, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol 2003; 14:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/49\">",
"      Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004; 43:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/50\">",
"      McPate MJ, Duncan RS, Witchel HJ, Hancox JC. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 2006; 41:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/51\">",
"      Mizobuchi M, Enjoji Y, Yamamoto R, et al. Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties. Pacing Clin Electrophysiol 2008; 31:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19417/abstract/52\">",
"      Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 2005; 16:394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16697 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19417=[""].join("\n");
var outline_f18_61_19417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1561601237\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601136\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601143\">",
"      HISTORICAL BACKGROUND, INITIAL REPORT, AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5697920\">",
"      PREVALENCE OF A SHORT QT INTERVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601157\">",
"      GENETIC BASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175416\">",
"      CELLULAR BASIS OF ARRHYTHMOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601164\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H339863\">",
"      Initial presentation by SQTS subtype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601171\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341508\">",
"      Electrocardiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601193\">",
"      Electrophysiological study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175129\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3739469511\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3633016551\">",
"      Screening family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341687\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H616552\">",
"      Normal variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175259\">",
"      Acquired causes of short QT interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175234\">",
"      Deceleration-dependent shortening of the QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601207\">",
"      MANAGEMENT OF PATIENTS WITH A SHORT QT INTERVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3288843\">",
"      Patients with an isolated short QT interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3288858\">",
"      Patients with a short QT interval who have a high probability of SQTS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601214\">",
"      - Implantable cardioverter-defibrillator (ICD)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601230\">",
"      - Pharmacological therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1561601237\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/16697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16697|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/3/33852\" title=\"figure 1\">",
"      ECG and action potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/59/20401\" title=\"figure 2\">",
"      Action potential currents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16697|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/60/33740\" title=\"table 1\">",
"      Genetic basis of SQTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/14/34028\" title=\"table 2\">",
"      Proposed diagnostic criteria for short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/35/5691\" title=\"table 3\">",
"      Secondary causes of short QT interval on ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 4\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16697|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?38/15/39158\" title=\"waveform 1\">",
"      Electrocardiographic characteristics of the short QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?7/48/7937?source=related_link\" title=\"calculator 1\">",
"      Calculator: QT Interval Correction (EKG)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37687?source=related_link\">",
"      ECG tutorial: Basic principles of ECG analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/2/12326?source=related_link\">",
"      Overview of invasive cardiac electrophysiology studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=related_link\">",
"      Pathophysiology of the long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_61_19418="Standard childhood vaccines: Parental hesitancy or refusal";
var content_f18_61_19418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Standard childhood vaccines: Parental hesitancy or refusal",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19418/contributors\">",
"     Julie A Boom, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19418/contributors\">",
"     C Mary Healy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19418/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19418/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19418/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/61/19418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/61/19418/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/61/19418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic reviews the reasons why some parents refuse or are hesitant to have their child(ren) immunized; the consequences of vaccine refusal; and an approach to the management of parents who refuse vaccines for their children. Standard childhood immunizations for children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization is one of the most effective preventative health measures and has saved countless children from death or serious disability (",
"    <a class=\"graphic graphic_figure graphicRef58899 \" href=\"UTD.htm?10/25/10645\">",
"     figure 1",
"    </a>",
"    ). Despite this, immunization is an emotional issue for many parents. As vaccine-preventable diseases become less common and parents have little familiarity with the devastating effects of vaccine-preventable illnesses, the benefits of immunization may seem less important than the potential adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mainstream media and Internet discussions on vaccines, fueled by celebrity opinion, often give equal or greater weight to ill-informed opinion or anecdotal claims about the dangers of vaccines compared with the rigorous scientific studies that prove vaccines are safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The mainstream media has a limited ability (or perhaps preference) to adequately communicate scientific data on vaccines, and Internet sites are not subject to constraints regarding scientific accuracy or fairness of their reporting. The resulting misinformation leads to unnecessary parental concerns. Healthcare providers need to understand these concerns in order to effectively address them and aid parents in choosing immunization for their children. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Approach to management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STATE LAWS REGARDING VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All 50 states in the United States require some immunizations for school entry (typically for kindergarten, seventh grade, and college entry). However, parents can elect to exempt their children from immunizations. There are three types of exemption:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical exemptions are for children who have a valid medical contraindication to a vaccine or vaccine component (eg, history of anaphylaxis to a previous dose of vaccine).",
"     </li>",
"     <li>",
"      Religious exemptions are for individuals whose religious beliefs oppose immunizations.",
"     </li>",
"     <li>",
"      Philosophical exemptions are for individuals with a personal, moral, or philosophical belief against some or all immunizations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All states allow medical exemptions; nearly all allow exemptions based upon religious beliefs, and approximately 40 percent allow philosophical exemptions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/5\">",
"     5",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://www.ncsl.org/issues-research/health/school-immunization-exemption-state-laws.aspx\">",
"     National Conference of State Legislatures",
"    </a>",
"    provides a comprehensive list of state exemption statutes.",
"   </p>",
"   <p>",
"    Observational studies suggest that the ease with which exemptions can be obtained impacts exemption rates within communities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. States that allow philosophical and religious exemptions have significantly higher vaccine exemption rates than those with religious exemptions only [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/10\">",
"     10",
"    </a>",
"    ]. They also have higher rates of vaccine-preventable diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. The Pediatric Infectious Diseases Society is opposed to legislation that permits philosophical exemption to mandatory immunizations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Consequences of vaccine refusal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of vaccine refusal remains low. In a 1999 national survey, immunizations were rated as extremely important by 87 percent of parents, and 84 percent said they would not decline any immunizations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/13\">",
"     13",
"    </a>",
"    ]. In a 2009 national survey of parents or guardians of children &le;6 years of age, 93.4 percent indicated that their youngest child had or would receive all recommended vaccines, but only 80 percent reported believing that immunizations were very important to children&rsquo;s health [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the majority of parents agree to have their children immunized, vaccine refusal appears to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/5,9,13,15-18\">",
"     5,9,13,15-18",
"    </a>",
"    ]. The proportion of children who are exempted from school immunization requirements for nonmedical reasons is the primary measure of vaccine refusal in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/5\">",
"     5",
"    </a>",
"    ]. Between 1991 and 2004, the mean rate of nonmedical immunization exemptions at kindergarten entry increased from 0.98 to 1.48 percent at the state level. Among states that allowed exemptions for",
"    <span class=\"nowrap\">",
"     philosophical/personal",
"    </span>",
"    beliefs, the nonmedical exemption rate increased to 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/6\">",
"     6",
"    </a>",
"    ]. The rate of nonmedical exemptions at kindergarten entry varies geographically (ranging from 1.1 to 24.2 percent by county in Washington state for 2010-2011; and from 0.4 to 5.8 percent for 2011-2012 nationally) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In the 2003 and 2004 National Immunization Survey (NIS), 6 percent of parents reported having refused at least one vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/15\">",
"     15",
"    </a>",
"    ]. In another national survey, 11.5 percent of parents reported having refused at least one vaccine in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many parents express concerns related to vaccines, even if they choose to vaccinate their children. In a 1999 national survey, 25 percent of parents expressed vaccine concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/13\">",
"     13",
"    </a>",
"    ]. In the 2003 and 2004 NIS, 9 percent of parents reported that they allowed their child to be immunized but were doubtful it was the correct thing to do, and 13 percent reported having delayed a vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/15\">",
"     15",
"    </a>",
"    ]. Approximately 90 percent of pediatric healthcare providers annually encounter at least one parent who refuses some recommended vaccines, and 54 percent encounter a parent who refuses all recommended vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/16,21\">",
"     16,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Demographics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are important",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    and socioeconomic differences between children who have received fewer than the recommended number of vaccines (undervaccinated children) and children who have received no vaccines (unvaccinated children) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In the 2001 NIS,",
"    <strong>",
"     undervaccinated",
"    </strong>",
"    children were more likely to be black, live in poverty in a central city, and have an unmarried younger mother without a college education [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast,",
"    <strong>",
"     unvaccinated",
"    </strong>",
"    children were more likely to be white, have a married mother with a college degree, and have an annual family income greater than $75,000. Additional studies confirm that parents who refuse vaccines or seek philosophical exemptions are older (36 to 40 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/25\">",
"     25",
"    </a>",
"    ] and have higher levels of education and household incomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Unvaccinated children also tend to live in states that allow philosophical exemption, and cluster in certain counties [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/22,28\">",
"     22,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents who seek vaccine exemptions may have a low level of trust in the government and healthcare professionals and may use complementary or alternative medicine professionals whom they consider to be reliable sources of vaccine information [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/25\">",
"     25",
"    </a>",
"    ]. In a 2002 national survey, 12 percent of respondents who had at least one child &lt;18 years of age living in the household were opposed to compulsory vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/23\">",
"     23",
"    </a>",
"    ]. Many of those opposed to compulsory vaccination believed that vaccines were not necessary for protection against disease and did not plan to fully immunize their youngest child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vaccine beliefs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scientific characterization of parents according to vaccine beliefs is difficult. One study from the Centers for Disease Control and Prevention (CDC) has identified five types of parents, according to clusters of attitudes and beliefs about vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Immunization advocates\" (33 percent) strongly agree that vaccines are necessary, safe and important",
"     </li>",
"     <li>",
"      \"Go along to get alongs\" (26 percent) agree that vaccines are necessary and safe",
"     </li>",
"     <li>",
"      \"Health advocates\" (25 percent) agree that vaccines are necessary but are less sure about their safety",
"     </li>",
"     <li>",
"      \"Fence-sitters\" (13 percent) slightly agree that vaccines are necessary and safe",
"     </li>",
"     <li>",
"      \"Worrieds\" (3 percent) slightly disagree that vaccines are necessary and strongly disagree that they are safe",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parental types also differ in their descriptions of their relationship with their provider, varying from \"good,\" for immunization advocates, to \"neutral,\" for fence-sitters and worrieds [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/29\">",
"     29",
"    </a>",
"    ]. Worrieds are also skeptical that providers have their child's best interest at heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     WHY PARENTS REFUSE VACCINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General objections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parental concerns regarding vaccines can be classified into several major categories that have remained relatively unchanged since the advent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/24/18823?source=see_link\">",
"     smallpox vaccination",
"    </a>",
"    in the 18th century: concerns about safety or side effects, religious objections (immunizations are a violation of God's will), and philosophical objections (immunization is \"not natural\") [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/16,17,25,30-33\">",
"     16,17,25,30-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns about safety and side effects account for approximately 60 to 70 percent of vaccine exemption requests [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/25,27,31\">",
"     25,27,31",
"    </a>",
"    ]. Specific safety concerns include particular side effects (eg, Guillain-Barr&eacute; syndrome, intussusception) and concerns that vaccines overload the immune system, possibly causing autism, autoimmune disease, or increased susceptibility to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/13,25\">",
"     13,25",
"    </a>",
"    ]. Some safety concerns have a factual basis (eg, an early",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    [Rotashield] and intussusception), whereas others are misconceptions (that multiple vaccines overwhelm the immune system) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/34\">",
"     34",
"    </a>",
"    ]. Concerns about safety are intensified by negative word of mouth and media messages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/3,16\">",
"     3,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional reasons for vaccine refusal include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/14,16,17,25,31,34,35\">",
"     14,16,17,25,31,34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Concern that vaccines don't work",
"     </li>",
"     <li>",
"      Concerns about medical contraindications",
"     </li>",
"     <li>",
"      Antigovernment sentiment",
"     </li>",
"     <li>",
"      Belief that their child is not at risk",
"     </li>",
"     <li>",
"      Belief that the disease is not dangerous",
"     </li>",
"     <li>",
"      Belief that is it better to be naturally infected than vaccinated",
"     </li>",
"     <li>",
"      Cost",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Belief that the child is not at risk or that the disease is not dangerous is a consequence of the success of childhood immunization programs (",
"    <a class=\"graphic graphic_figure graphicRef58899 \" href=\"UTD.htm?10/25/10645\">",
"     figure 1",
"    </a>",
"    ). As more diseases are successfully prevented by immunization, the devastating sequelae of vaccine-preventable diseases are forgotten [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1\">",
"     1",
"    </a>",
"    ]. Many parents are unaware of the risks to the individual and of the societal consequences of refusing vaccines. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Consequences of vaccine refusal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Specific objections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents (and providers) may have a tendency to selectively protect against diseases they believe are more severe (eg, Haemophilus influenzae type b) and refuse vaccines against diseases that they believe are not dangerous. As an example,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is one of the more commonly refused vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/5,36,37\">",
"     5,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies demonstrate that underimmunized children have characteristics reflecting social inequalities, rather than true philosophical objections to immunization. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Demographics'",
"    </a>",
"    above.) However, there is some evidence to suggest that parents whose children were underimmunized for pertussis, hepatitis B, or measles had safety concerns (eg, autism, thimerosal) and wished to selectively immunize their children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/22,38\">",
"     22,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     MMR vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern regarding the combination",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12215?source=see_link\">",
"     measles-mumps-rubella vaccine",
"    </a>",
"    (MMR) can be traced to a 1998 study in 12 children from the United Kingdom (UK) alleging that MMR damaged the intestinal lining, allowing encephalopathic proteins to enter the bloodstream and brain, thereby leading to the development of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/39\">",
"     39",
"    </a>",
"    ]. The paper was retracted from the public record in 2010, and exposed as fraudulent in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Despite overwhelming evidence disproving this theory, it still is highlighted in media reports and on the Internet [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/2\">",
"     2",
"    </a>",
"    ]. Large-scale population studies have demonstrated that MMR and autism occur independently of each other and that gastrointestinal disease and autism do not occur after MMR vaccine. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=see_link&amp;anchor=H4#H4\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\", section on 'Enterocolitis and regression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the lack of an association between autism and MMR, MMR immunization rates in the UK declined acutely (from 92 percent in 1995 to 79 percent in 2003) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In June 2008, measles was again endemic in the UK, 14 years after it had been eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HPV vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) vaccine is controversial for some patients and providers. Attitudes of parents, partners, and clinicians influence completion of the vaccine series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/46\">",
"     46",
"    </a>",
"    ]. Concerns regarding HPV vaccine are related to the belief that it may encourage sexual activity, excessive influence by the pharmaceutical industry [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/35\">",
"     35",
"    </a>",
"    ]. The 2009 death of a British girl within hours of receiving HPV vaccine received widespread attention; autopsy demonstrated that she died of an undiagnosed tumor and that her death was unrelated to HPV [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The media focus on the above concerns may have contributed to the number of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) between June 2006 and December 2008 (53.9 per 100,000 doses administered, 6.2 percent serious) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/50\">",
"     50",
"    </a>",
"    ]. However, analysis of the VAERS reports shows that the adverse events were similar to those identified before the vaccine was licensed. They were also similar to background rates of other vaccine-associated adverse events, except for two categories: syncope and venous thromboembolism. The age group for whom HPV vaccine is recommended (11 to 26 years) has an excess risk of immunization-associated syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/51\">",
"     51",
"    </a>",
"    ]. Studies are ongoing to further quantify the excess risk, if any, of HPV-vaccine-associated thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H21#H21\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Vaccine safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Meningococcal conjugate vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major concern regarding the quadrivalent meningococcal conjugate vaccine is a possible association with Guillain-Barr&eacute; syndrome (GBS) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/52\">",
"     52",
"    </a>",
"    ]. GBS is an immune-mediated, rapidly evolving polyradiculoneuropathy with an estimated incidence of 1 to 2 cases per 100,000 person-years. Although GBS has been",
"    <strong>",
"     temporally",
"    </strong>",
"    associated with vaccination, a",
"    <strong>",
"     causal",
"    </strong>",
"    association has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\", section on 'Epidemiology'",
"    </a>",
"    .) The possible association between quadrivalent meningococcal conjugate vaccine and GBS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link&amp;anchor=H9#H9\">",
"     \"Meningococcal vaccines\", section on 'Possible association with Guillain-Barr&eacute; syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parental concerns regarding influenza vaccines may include unknown side effects with possible long-term problems, Guillain-Barr&eacute; syndrome (GBS), thimerosal exposure, inadequate testing to ensure safety in children, and the lack of need for protection against what may be mistakenly thought of as a \"mild type\" of influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns about influenza-vaccine-associated GBS and other neurologic complications were highlighted by the media during the 2009 H1N1 influenza pandemic. Cases of GBS occurred following the administration of swine flu vaccine in the United States in 1976 and 1977, and some commentators erroneously compared the rapid development of H1N1 vaccines to swine flu vaccine development in 1976. However, monovalent H1N1 vaccine was developed using the same methods that are used for seasonal influenza vaccine, and the increased risk of GBS following seasonal influenza vaccine is small or nonexistent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H21#H21\">",
"     \"Seasonal influenza vaccination in children\", section on 'Adverse reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H29#H29\">",
"     \"Seasonal influenza vaccination in children\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies regarding adverse effects of monovalent H1N1 vaccines indicate that the risk of GBS following monovalent H1N1 vaccine is minimally, if at all, increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H415326#H415326\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Guillain-Barr&eacute; syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Thimerosal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of thimerosal (ethylmercury) as a vaccine preservative has been hypothesized to result in mercury-related neurologic effects, including the development of autism. Numerous studies refute this hypothesis. Nonetheless, some parents remain unconvinced by the scientific data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF VACCINE REFUSAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine refusal increases the risk of vaccine-preventable disease among unvaccinated individuals and the risk of vaccine-preventable disease outbreaks in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     For the individual",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unvaccinated children have a higher risk of acquiring vaccine-preventable illness than their vaccinated peers. In observational studies and mathematical modeling, the magnitude of the increased risk is approximately ninefold for varicella and ranges from 22- to 35-fold for measles and 6- to 23-fold for pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During January-July 2008, 123 measles cases occurred in residents of the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/44\">",
"       44",
"      </a>",
"      ]. Ninety-one percent of these cases occurred in individuals who were unvaccinated or did not have evidence of vaccination; among the 95 cases who were eligible for immunization, two-thirds were unvaccinated because of religious or philosophical beliefs (",
"      <a class=\"graphic graphic_figure graphicRef77049 \" href=\"UTD.htm?32/9/32926\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among Colorado children enrolled in a large health plan, 11 percent of pertussis cases were attributed to vaccine refusal [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2008 outbreak of invasive Haemophilus influenzae type b (Hib) disease in Minnesota, Hib vaccination was deferred or refused by the guardians of three of the five cases; one of these children died from Hib meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risks of delaying immunization have not been well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/5\">",
"     5",
"    </a>",
"    ]. As a general rule, young children are at greater risk for severe disease than older children who contract vaccine-preventable illnesses (eg, pertussis, influenza). Delaying immunizations increases the duration of vulnerability for these young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     For the community",
"    </span>",
"    &nbsp;&mdash;&nbsp;The public health consequences of vaccine refusal are demonstrated by multiple outbreaks of vaccine-preventable diseases in unvaccinated individuals, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 1985 and 1994, 13 disease outbreaks occurred in religious groups opposed to immunization, resulting in 1200 cases and 9 deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A measles outbreak at a college for Christian Scientist students resulted in 125 cases (attack rate 15 percent) and three deaths (case fatality rate 2.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/61\">",
"       61",
"      </a>",
"      ]. Another measles outbreak at a camp attended by Christian Scientists had an attack rate of 25.2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Outbreaks of polio, rubella, measles, pertussis (345 cases, attack rate 20 percent), and Haemophilus influenzae type b (Hib) have been reported in undervaccinated Amish communities [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/62-68\">",
"       62-68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measles outbreaks occur on a regular basis in Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/45,69\">",
"       45,69",
"      </a>",
"      ] and were reported across the United States during 2008, mainly among children whose parents had refused immunization [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/44,70\">",
"       44,70",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'MMR vaccine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'For the individual'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suboptimal vaccination rates also result in disease outbreaks and deaths among vaccinated individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/57,71\">",
"     57,71",
"    </a>",
"    ]. Vaccinated children may acquire infection through contact with vaccine exemptors. Rates of disease among vaccinated individuals increase as vaccinated and unvaccinated individuals mix in communities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of children aged 3 to 18 years, the frequency of vaccine exemptors directly correlated with the incidence of measles and pertussis in vaccinated children [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/57\">",
"       57",
"      </a>",
"      ]. Schools with pertussis outbreaks had more vaccine exemptors than schools without outbreaks (4.3 versus 1.5 percent of students).",
"     </li>",
"     <li>",
"      In an observational study, there was significant overlap between census tracts with clusters of pertussis and census tracts with clusters of nonmedical exemptions (odds ratio 2.7, 95% CI 2.2-3.3) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overview of approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parental vaccine refusal may evoke strong emotional responses in medical providers, ranging from issues of trust in their relationships with patients to medicolegal concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/34\">",
"     34",
"    </a>",
"    ]. It may be difficult to put aside these initial reactions, but establishing a nonconfrontational dialogue from the first clinician-parent interaction is essential to ensuring a successful result. The healthcare provider is one of the most important influences in decisions about immunization, even among vaccine-hesitant parents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/14,22,25,33,72,73\">",
"     14,22,25,33,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When faced with vaccine-hesitant parents, the provider should be guided by the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish open, ongoing, nonconfrontational dialogue to identify concerns.",
"     </li>",
"     <li>",
"      Target education to address specific parental concerns, using a variety of resources (",
"      <a class=\"graphic graphic_table graphicRef82687 \" href=\"UTD.htm?13/56/14223\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Maintain the provider-patient relationship.",
"     </li>",
"     <li>",
"      Use vaccine schedules that deviate from the recommended schedule (eg, the schedule recommended by Centers for Disease Control, American Academy of Pediatrics, and American Academy of Family Physicians in the United States) (",
"      <a class=\"graphic graphic_figure graphicRef82617 graphicRef58209 \" href=\"UTD.htm?4/7/4218\">",
"       figure 3A-B",
"      </a>",
"      ) only when other options, such as targeted education, have failed and the family would otherwise refuse vaccination entirely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Establish dialogue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialogue should begin at the first provider-parent encounter and continue at every subsequent interaction. The dialogue is more important than the outcome at any one visit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/75\">",
"     75",
"    </a>",
"    ]. Providers must listen to their patients' parents to identify the forces that influence vaccine concerns. Once the concerns are identified, the provider can establish a plan for targeted education to address them. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Why parents refuse vaccines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Key points in establishing the dialogue include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acknowledging a shared goal (what is best for the child)",
"     </li>",
"     <li>",
"      Acknowledging the large volume of complex, conflicting information about vaccine benefits and safety",
"     </li>",
"     <li>",
"      Offering to help them to gather the best information to make an informed decision (",
"      <a class=\"graphic graphic_table graphicRef82687 \" href=\"UTD.htm?13/56/14223\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Identify concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respectful listening is critical in identifying the source of parental concerns. Parents receive vaccine information from media reports that grab audience attention, present information that is easy to understand, and highlight pro- and antivaccine viewpoints in a limited time frame. A few sensational, anecdotal reports alleging harm may receive equal or greater attention than large-scale population studies that prove vaccine safety [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1\">",
"     1",
"    </a>",
"    ]. Erroneous impressions regarding vaccine safety may be supplemented by stories parents have heard from family or friends or have read on the Internet. Visual imagery of children allegedly hurt by vaccines is more compelling than faceless statistics about diseases parents have never seen or experienced.",
"   </p>",
"   <p>",
"    Some parental concerns may not be immediately obvious. Parents may be concerned that their infant will suffer during vaccine administration. They may fear",
"    <strong>",
"     committing",
"    </strong>",
"    harm (giving an unsafe vaccine) more than",
"    <strong>",
"     allowing",
"    </strong>",
"    harm (taking a chance that their child will develop a disease). Providers must listen carefully and respectfully to understand these concerns, even if it is time consuming.",
"   </p>",
"   <p>",
"    One author provides a practical approach to categorizing vaccine-hesitant parents according to the source and conviction of their concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"uninformed but educable\" have received an antivaccine message from families or friends but seek information to counter this.",
"     </li>",
"     <li>",
"      The \"misinformed but correctable\" have been influenced by antivaccine messages from the media or the Internet but are relatively unaware of medically accurate provaccination arguments.",
"     </li>",
"     <li>",
"      The \"well-read and open-minded\" have explored the pro- and antivaccination messages but want their provider's input in interpreting the information.",
"     </li>",
"     <li>",
"      The \"convinced and contented\" are strongly antivaccination but want to demonstrate their willingness to listen to the other side of the argument (often to satisfy a family member).",
"     </li>",
"     <li>",
"      The \"committed and missionary\" are strongly antivaccine and want to convince the provider to agree with their arguments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three groups tend to respond positively to information and dialogue, whereas the latter two are unlikely ever to change their position, although the \"convinced and contented\" may moderate their beliefs over time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Target education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most parental vaccine concerns are amenable to dialogue and discussion. Providers should target education to specific parental concerns",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beliefs, realizing that some parents may need information from a variety of resources (",
"    <a class=\"graphic graphic_table graphicRef82687 \" href=\"UTD.htm?13/56/14223\">",
"     table 1",
"    </a>",
"    ). Visual imagery and anecdotes from parents who are vaccine advocates may be used to support the educational message (eg,",
"    <a class=\"external\" href=\"file://www.familiesfightingflu.org/\">",
"     Families Fighting Flu",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.meningitis-angels.org/\">",
"     Meningitis Angels",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.nmaus.org/\">",
"     National Meningitis Association",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.texaschildrens.org/vaccine/\">",
"     Vaccine-preventable disease: The forgotten story",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Focused education that directly addresses the source of vaccine concerns may have an important impact [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/16,77\">",
"     16,77",
"    </a>",
"    ]. However, data are lacking on the overall success rates of education. The HealthStyles survey indicates that approximately one-third of parents want more information about immunizations and that the healthcare provider is one of the most influential factors in decisions about immunization, even among vaccine-hesitant parents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/22,25,72,78\">",
"     22,25,72,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Targeted immunization materials that provide unbiased, accurate statistical information, avoid scare tactics, and are not judgmental may be helpful in improving immunization acceptance in certain groups of vaccine-hesitant parents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/38,79\">",
"     38,79",
"    </a>",
"    ]. Parents are skeptical of aggressive pro-and antivaccine messages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/16\">",
"     16",
"    </a>",
"    ]. Emphasizing mandatory school entry requirements in an effort to influence parents is not helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The provider must address relevant concerns while fully explaining vaccine benefits and risks. Potential areas for targeted education include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vaccine limitations",
"     </li>",
"     <li>",
"      Adverse events",
"     </li>",
"     <li>",
"      Misconceptions",
"     </li>",
"     <li>",
"      Pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Vaccine limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to acknowledge that although vaccines are very safe, they are not completely risk free or 100 percent effective. Providing this information is important in establishing credibility, but the information must be placed in a proper context for parents who may overestimate the risks of vaccines and underestimate the risks from vaccine-preventable diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1\">",
"     1",
"    </a>",
"    ]. It may be helpful to reframe the discussion by defining the options in terms of benefits with risks, rather than emphasizing the risks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events related to vaccines must be put into context. Most vaccine-associated adverse events are minor and self-limited (eg, local skin reactions, transient low-grade fever). Serious adverse events from an individual vaccine occur rarely, but these should be weighed against the risks associated with the natural infection. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of acquiring measles during an outbreak may be 35 times higher in an unvaccinated than in a vaccinated person [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of measles-associated encephalopathy or subacute sclerosing panencephalitis following natural measles is 1000 times higher than the risk of encephalopathy from measles vaccine (1 in 1 million) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Misconceptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to dispel myths, correct misinformation, and direct parents to scientifically sound information (",
"    <a class=\"graphic graphic_table graphicRef82687 \" href=\"UTD.htm?13/56/14223\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/34\">",
"     34",
"    </a>",
"    ]. Providers should avoid using ambiguous language or complicated scientific terms when communicating the science supporting vaccine safety and effectiveness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autism &ndash; The most common vaccine myth, that vaccines cause autism, has suggested a number of hypotheses to substantiate the link (eg, that MMR or thimerosal [ethylmercury] cause autism). The myths related to autism and MMR and thimerosal are discussed separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=see_link\">",
"       \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=see_link\">",
"       \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Overwhelming the immune system &ndash; Parents may worry that multiple vaccines overwhelm the immune system, possibly causing autism, autoimmune disease, or susceptibility to infections. The following observations provide evidence against this claim [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With manufacturing advances and discontinuation of smallpox immunization, children are exposed to fewer antigens today than they were in 1980 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/34\">",
"       34",
"      </a>",
"      ]. The currently recommended immunizations for children younger than two years (",
"      <a class=\"graphic graphic_figure graphicRef82617 graphicRef58209 \" href=\"UTD.htm?4/7/4218\">",
"       figure 3A-B",
"      </a>",
"      ) contain &lt;200 bacterial and viral protein or polysaccharide antigens, compared with &gt;3000 such antigens in the seven vaccines administered in 1980 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The infant immune system can respond to multiple antigens (conservative estimates suggest thousands) simultaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/34,85,86\">",
"       34,85,86",
"      </a>",
"      ]. This is illustrated by the observations that mild or moderate illness does not interfere with an infant's ability to generate protective immune responses to vaccines and that combinations of vaccines induce immune responses comparable to those given individually [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vaccinated and unvaccinated children do not differ in their susceptibility to infectious diseases for which there are no vaccines (eg, enterovirus, candida) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/87-89\">",
"       87-89",
"      </a>",
"      ]. On the other hand, infection with vaccine-preventable disease can predispose to severe invasive infections with other pathogens (eg, methicillin-resistant Staphylococcus aureus) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/90,91\">",
"       90,91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccines are not necessary &ndash; As vaccine-preventable diseases become less common and parents have little familiarity with the devastating effects of vaccine-preventable illnesses, some parents may believe that vaccines are no longer necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1\">",
"       1",
"      </a>",
"      ]. These parents must be educated regarding the persistence of vaccine-preventable diseases and the potential for a rapid increase in vaccine-preventable disease incidence when immunization rates decline [",
"      <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Consequences of vaccine refusal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers can educate parents on available methods to reduce pain when multiple vaccine injections are required at a single visit. These may include nonpharmacologic options, such as oral sucrose for infants; stroking, rocking, or \"blowing the pain away for older children\"; or pharmacologic management if indicated (eg, topical anesthetics placed 30 to 60 minutes prior to injection) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/92-94\">",
"     92-94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Maintain relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;When educational efforts fail to persuade parents to immunize their children, providers may be faced with a dilemma about whether or not to refer the family to another provider [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Factors influencing this decision include lack of shared goals, absence of trust in the clinician-family relationship, and fear of litigation if the child subsequently contracts a vaccine-preventable disease or transmits a vaccine-preventable disease to an individual with vaccine contraindications or who was too young to be immunized [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/96\">",
"     96",
"    </a>",
"    ]. Although we recognize that a provider may choose to dismiss a family form his or her practice when poor communication and distrust have become insurmountable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/97\">",
"     97",
"    </a>",
"    ], we encourage providers to maintain relationships with families who refuse immunization.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics (AAP) Committee on Bioethics advises against discontinuing care for families who refuse or delay vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/74\">",
"     74",
"    </a>",
"    ]. The decision to immunize belongs, ultimately, to the parents. The benefits of immunization must be weighed against those of the provider maintaining a positive relationship with the family. Maintenance of the relationship permits time for ongoing dialogue and targeted education and ensures that the child has a medical home.",
"   </p>",
"   <p>",
"    Although the AAP Committee on Bioethics acknowledges that the welfare of the child is paramount, it advises providers to tolerate parental decisions \"not likely to be harmful to the child\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/74\">",
"     74",
"    </a>",
"    ]. Using this paradigm, immunization of an individual child is favored when community immunization rates are low and disease prevalence is high, or if the child has a medical predisposition to a disease. The risk to the community attributable to unimmunized children infecting children who are unable to be immunized and the community cost of caring for children with vaccine-preventable diseases should also be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Rarely, providers may be obliged to involve state agencies to provide immunization against parental wishes (eg, when a child is placed at risk during an epidemic) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Consequences of vaccine refusal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The AAP advises that dismissing vaccine-refusing families should be an option of last resort but recognizes that distrust and poor communication may, rarely, make termination of the clinician-patient relationship advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/74\">",
"     74",
"    </a>",
"    ]. In this unusual situation, the provider should offer sufficient information to assist families to find another provider and allow adequate time for the transition to occur, thus avoiding potentially harmful lapses in medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Alternative schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deviations from the recommended childhood immunization schedule should be used only when all other options have failed. Alternative schedules should not be used as a substitute for establishing parental dialogue or targeted education [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1,74\">",
"     1,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative schedules are not founded in science and entail multiple visits to the provider's office. A committee convened by the Institute of Medicine to study the health outcomes related to the recommended childhood immunization schedule in the United States found no conclusive evidence of adverse events related to multiple immunizations or other aspects of the immunization schedule, suggesting that the current recommended schedule is safe [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/100\">",
"     100",
"    </a>",
"    ]. Alternative schedules increase the risk of noncompliance and the duration of vulnerability to vaccine-preventable diseases. However, the use of an alternative schedule may allay the fears of some parents enough that they permit their child to be immunized.",
"   </p>",
"   <p>",
"    The most popular of the alternative immunization schedules are the \"selective vaccine schedule\" and \"alternative vaccine schedule\" published by Dr. Robert Sears [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/101\">",
"     101",
"    </a>",
"    ]. Dr. Sears's book casts doubt on clinicians' understanding of vaccine research and the motives of the pharmaceutical industry and suggests that the immunization schedule recommended by the Centers for Disease Control and Prevention, American Academy of Pediatrics, and American Academy of Family Physicians is in the public's, but not necessarily the individual's, best interest. His alternative schedules prioritize immunizations that he considers more important on the basis of his experience as a pediatrician in private practice, while delaying or skipping others. Only two vaccines are administered at a time, and only one aluminum-containing vaccine is given at any one visit.",
"   </p>",
"   <p>",
"    Although Dr. Sears's approach may seem to be a reasonable compromise between hesitant parents and their providers, there are multiple inherent problems. Critics of Dr. Sears's book explain in detail how it fails to distinguish good from bad science when discussing vaccine research, misinterprets vaccine safety data, underestimates the risks to children of vaccine-preventable diseases by considering only his limited personal experience, is ambiguous regarding the disproven associations of MMR and thimerosal with autism, and does not fully grasp the scientific method [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Timely receipt of vaccines during the first year of life has no adverse effect on neuropsychologic outcomes. Review of data from the Vaccine Safety Datalink study, which included 1047 children, indicate that the 47 percent of children who received their vaccines on time (&ge;2 hepatitis B, three diphtheria-tetanus-pertussis, three Haemophilus influenzae type b, and two polio vaccines within 30 days of the recommended age) performed as well or better at age 7 to 10 years on every measure of neuropsychologic outcome than the 23 percent of children who received all of the recommended vaccines, but not on time; and the 20 percent of children who did not receive all of the recommended vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The schedules proposed in Dr. Sears's book are potentially harmful, extending the duration of vulnerability for vaccine-preventable diseases that continue to cause outbreaks. For example, under the \"alternative\" schedule, it is recommended that MMR be separated into three components: mumps is given at 12 months, rubella at two years, and measles at three years. Single-antigen measles vaccine is no longer available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/104\">",
"     104",
"    </a>",
"    ]. Under the \"selective\" schedule, titers for measles, mumps, and rubella are checked at age 10 years, and vaccination considered if not immune. Delayed administration of polio, varicella, hepatitis A, and hepatitis B vaccines is also suggested for reasons that are not founded in science.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Special precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have not been immunized are at risk to develop or transmit vaccine-preventable disease. Parents of children who refuse immunizations must take special precautions with respect to these risks. When their child is ill, they must inform the healthcare providers that the child has not been vaccinated so that the providers can consider vaccine-preventable illnesses in their differential diagnosis and take the necessary steps to prevent infection of other patients. The Centers for Disease Control and Prevention, American Academy of Pediatrics, and American Academy of Family Physicians has developed a handout for parents to remind them of these risks and responsibilities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers should document each discussion with parents about the risks of not immunizing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/74\">",
"     74",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) has developed guidelines for providers faced with this situation and provides sample waiver documentation to cover this eventuality (available through the",
"    <a class=\"external\" href=\"file://www2.aap.org/immunization/pediatricians/pdf/RefusaltoVaccinate.pdf\">",
"     American Academy of Pediatrics",
"    </a>",
"    ). Another sample waiver is available through the",
"    <a class=\"external\" href=\"file://www.immunize.org/nslt.d/n50/refusal.pdf\">",
"     Immunization Action Coalition",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific strategies to prevent parental vaccine refusal have not been studied. However, given that primary care providers are one of the most influential factors in decisions about immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/22,25,72\">",
"     22,25,72",
"    </a>",
"    ], it is reasonable for providers to establish open, honest, nonconfrontational dialogue about the importance of childhood vaccinations beginning with the first provider-parent interaction. Providers also should share their own or their practice's philosophy regarding delaying or refusing vaccination to avoid the potential for future disagreements.",
"   </p>",
"   <p>",
"    Education should start at the prenatal visit and continue at all subsequent well-child visits. At each encounter, providers should listen to parental concerns to identify sources of misinformation or other factors that may lead to vaccine hesitancy. Providers can then provide individualized education to address specific concerns or misconceptions.",
"   </p>",
"   <p>",
"    Education should be multifaceted, with providers answering questions unambiguously, avoiding complicated statistics, and providing information that is easily understood and \"personal.\" Providers should make full use of the online resources outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef82687 \" href=\"UTD.htm?13/56/14223\">",
"     table 1",
"    </a>",
"    ). Some parents may find the information on the Vaccine Information Statements adequate to address their needs, but others may require more detailed scientific information or may find simple question-and-answer pamphlets or personal testimonials from vaccine advocates more helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1,106\">",
"     1,106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most parents trust advice from their child's healthcare provider [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/22,25,72\">",
"     22,25,72",
"    </a>",
"    ]. However, it is useful for both parents and providers to access reputable sources where accurate and easy-to-understand vaccine information is available.",
"   </p>",
"   <p>",
"    Focus groups suggest that most parents trust information from the Centers for Disease Control and Prevention (CDC) or American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/79\">",
"     79",
"    </a>",
"    ]. A list of additional reputable vaccine Web sites is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef82687 \" href=\"UTD.htm?13/56/14223\">",
"     table 1",
"    </a>",
"    ). Parents who need more information than the clinician can provide during an office visit can be directed to these resources.",
"   </p>",
"   <p>",
"    Many of the organizations in the list provide publications or question-and-answer tear sheets that can be purchased or downloaded for use in office waiting rooms or for parents to take away and read. Posters and publications describing the consequences of vaccine-preventable diseases are also available for download or purchase from some of the sources in the table, which include public health agencies, organizations specializing in vaccine education, and parent-advocacy groups. The latter may be particularly useful for vaccine-hesitant parents because they highlight identifiable, serious, and sometimes fatal consequences of refusing immunization, using anecdotes and visual imagery to counter those used with such great effect by antivaccine activists [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For providers, the CDC, in partnership with the AAP and the American Academy of Family Physicians (AAFP), has developed",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/hcp/patient-ed/conversations/index.html\">",
"     Provider Resources for Vaccine Conversations with Parents",
"    </a>",
"    . They provide communication tips for providers, current vaccine safety information, answers to common questions, and disease-specific fact sheets that can be downloaded as a handout for parents to supplement Vaccine Information Statements and guide parent risk-benefit discussions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/61/19418/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunizations are one of the safest and most cost-effective preventative health measures (",
"      <a class=\"graphic graphic_figure graphicRef58899 \" href=\"UTD.htm?10/25/10645\">",
"       figure 1",
"      </a>",
"      ). However, misinformation may lead parents to hesitate or refuse to immunize their child(ren). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Concern about vaccine safety is the most common reason for vaccine refusal. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'General objections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccine refusal may result in vaccine-preventable disease in the individual",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      outbreaks of vaccine-preventable disease in unvaccinated and vaccinated individuals. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Consequences of vaccine refusal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The healthcare provider is one of the most influential factors in the decision whether or not to immunize a child. When faced with vaccine-hesitant parents, the provider should be guided by the following recommendations (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Overview of approach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Establish open, ongoing, nonconfrontational dialogue to identify concerns",
"     </li>",
"     <li>",
"      Target education to specific concerns, using a variety of resources (",
"      <a class=\"graphic graphic_table graphicRef82687 \" href=\"UTD.htm?13/56/14223\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maintain the provider-patient relationship",
"     </li>",
"     <li>",
"      Use vaccine schedules that deviate from the recommended schedule only when other options have failed and the family would otherwise refuse vaccination entirely",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Targeted education may include acknowledgment of vaccine limitations, provision of accurate estimates of the risks of adverse events and vaccine-preventable disease, correction of misconceptions, and discussion of techniques to alleviate immunization-related pain. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Target education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While we recognize that a provider may choose to dismiss a family from his or her practice when poor communication and distrust have become insurmountable, we encourage providers to maintain relationships with families who refuse immunization. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Maintain relationship'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest deviation from the recommended immunization schedule (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Alternative schedules'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/1\">",
"      Healy CM, Pickering LK. How to communicate with vaccine-hesitant parents. Pediatrics 2011; 127 Suppl 1:S127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/2\">",
"      Zimmerman RK, Wolfe RM, Fox DE, et al. Vaccine criticism on the World Wide Web. J Med Internet Res 2005; 7:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/3\">",
"      Leask JA, Chapman S. An attempt to swindle nature: press anti-immunisation reportage 1993-1997. Aust N Z J Public Health 1998; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/4\">",
"      Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web. Arch Dis Child 2002; 87:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/5\">",
"      Omer SB, Salmon DA, Orenstein WA, et al. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 2009; 360:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/6\">",
"      Omer SB, Pan WK, Halsey NA, et al. Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. JAMA 2006; 296:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/7\">",
"      Rota JS, Salmon DA, Rodewald LE, et al. Processes for obtaining nonmedical exemptions to state immunization laws. Am J Public Health 2001; 91:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/8\">",
"      Salmon DA, Omer SB, Moulton LH, et al. Exemptions to school immunization requirements: the role of school-level requirements, policies, and procedures. Am J Public Health 2005; 95:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/9\">",
"      Omer SB, Richards JL, Ward M, Bednarczyk RA. Vaccination policies and rates of exemption from immunization, 2005-2011. N Engl J Med 2012; 367:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/10\">",
"      Thompson JW, Tyson S, Card-Higginson P, et al. Impact of addition of philosophical exemptions on childhood immunization rates. Am J Prev Med 2007; 32:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/11\">",
"      Omer SB, Enger KS, Moulton LH, et al. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol 2008; 168:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/12\">",
"      A statement regarding personal belief exemption from immunization mandates: from the Pediatric Infectious Diseases Society, March 2011. Pediatr Infect Dis J 2011; 30:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/13\">",
"      Gellin BG, Maibach EW, Marcuse EK. Do parents understand immunizations? A national telephone survey. Pediatrics 2000; 106:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/14\">",
"      Kennedy A, Basket M, Sheedy K. Vaccine attitudes, concerns, and information sources reported by parents of young children: results from the 2009 HealthStyles survey. Pediatrics 2011; 127 Suppl 1:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/15\">",
"      Gust DA, Darling N, Kennedy A, Schwartz B. Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics 2008; 122:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/16\">",
"      Fredrickson DD, Davis TC, Arnould CL, et al. Childhood immunization refusal: provider and parent perceptions. Fam Med 2004; 36:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/17\">",
"      Freed GL, Clark SJ, Butchart AT, et al. Parental vaccine safety concerns in 2009. Pediatrics 2010; 125:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/18\">",
"      Robison SG, Groom H, Young C. Frequency of alternative immunization schedule use in a metropolitan area. Pediatrics 2012; 130:32.",
"     </a>",
"    </li>",
"    <li>",
"     Washington State Department of Health. Immunization &amp; Child Profile Office. School Status Data Reports, 2011. www.doh.wa.gov/cfh/immunize/schools/schooldatarprts.htm (Accessed on February 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/20\">",
"      Centers for Disease Control and Prevention (CDC). Vaccination coverage among children in kindergarten--United States, 2011-12 school year. MMWR Morb Mortal Wkly Rep 2012; 61:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/21\">",
"      Freed GL, Clark SJ, Hibbs BF, Santoli JM. Parental vaccine safety concerns. The experiences of pediatricians and family physicians. Am J Prev Med 2004; 26:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/22\">",
"      Smith PJ, Chu SY, Barker LE. Children who have received no vaccines: who are they and where do they live? Pediatrics 2004; 114:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/23\">",
"      Kennedy AM, Brown CJ, Gust DA. Vaccine beliefs of parents who oppose compulsory vaccination. Public Health Rep 2005; 120:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/24\">",
"      Jessop LJ, Kelleher CC, Murrin C, et al. Determinants of partial or no primary immunisations. Arch Dis Child 2010; 95:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/25\">",
"      Salmon DA, Moulton LH, Omer SB, et al. Factors associated with refusal of childhood vaccines among parents of school-aged children: a case-control study. Arch Pediatr Adolesc Med 2005; 159:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/26\">",
"      Wei F, Mullooly JP, Goodman M, et al. Identification and characteristics of vaccine refusers. BMC Pediatr 2009; 9:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/27\">",
"      Lawrence GL, Hull BP, MacIntyre CR, McIntyre PB. Reasons for incomplete immunisation among Australian children. A national survey of parents. Aust Fam Physician 2004; 33:568.",
"     </a>",
"    </li>",
"    <li>",
"     School Status Data Reports. Washington State Department of Health, 2009. Available at: www.doh.wa.gov/cfh/immunize/schools/schooldatarprts.htm (Accessed on November 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/29\">",
"      Gust D, Brown C, Sheedy K, et al. Immunization attitudes and beliefs among parents: beyond a dichotomous perspective. Am J Health Behav 2005; 29:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/30\">",
"      Wolfe RM, Sharp LK. Anti-vaccinationists past and present. BMJ 2002; 325:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/31\">",
"      Grossman Z, van Esso D, Del Torso S, et al. Primary care pediatricians' perceptions of vaccine refusal in europe. Pediatr Infect Dis J 2011; 30:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/32\">",
"      Wenger OK, McManus MD, Bower JR, Langkamp DL. Underimmunization in Ohio's Amish: parental fears are a greater obstacle than access to care. Pediatrics 2011; 128:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/33\">",
"      McCauley MM, Kennedy A, Basket M, Sheedy K. Exploring the choice to refuse or delay vaccines: a national survey of parents of 6- through 23-month-olds. Acad Pediatr 2012; 12:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/34\">",
"      Lyren A, Leonard E. Vaccine refusal: issues for the primary care physician. Clin Pediatr (Phila) 2006; 45:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/35\">",
"      Darden PM, Thompson DM, Roberts JR, et al. Reasons for not vaccinating adolescents: national immunization survey of teens, 2008-2010. Pediatrics 2013; 131:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/36\">",
"      Smith PJ, Santoli JM, Chu SY, et al. The association between having a medical home and vaccination coverage among children eligible for the vaccines for children program. Pediatrics 2005; 116:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/37\">",
"      Allred NJ, Wooten KG, Kong Y. The association of health insurance and continuous primary care in the medical home on vaccination coverage for 19- to 35-month-old children. Pediatrics 2007; 119 Suppl 1:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/38\">",
"      Gust DA, Strine TW, Maurice E, et al. Underimmunization among children: effects of vaccine safety concerns on immunization status. Pediatrics 2004; 114:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/39\">",
"      Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/40\">",
"      Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010; 375:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/41\">",
"      Deer B. How the case against the MMR vaccine was fixed. BMJ 2011; 342:c5347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/42\">",
"      Health Protection Agency. COVER programme: January to March 2003. Commun Dis Rep CDR Wkly (serial online) 2003; 13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/43\">",
"      Communicable Disease Surveillance Center. COVER/Korner July to September 1995. CDR Wkly 1995; 5:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/44\">",
"      Centers for Disease Control and Prevention (CDC). Update: measles--United States, January-July 2008. MMWR Morb Mortal Wkly Rep 2008; 57:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/45\">",
"      Measles once again endemic in the United Kingdom. Euro Surveill 2008; 13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/46\">",
"      Conroy K, Rosenthal SL, Zimet GD, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt) 2009; 18:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/47\">",
"      Rothman SM, Rothman DJ. Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 2009; 302:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/48\">",
"      Haug C. The risks and benefits of HPV vaccination. JAMA 2009; 302:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/49\">",
"      O'Dowd A. Teenager who died after having HPV vaccine had a malignant chest tumour. BMJ 2009; 339:b4032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/50\">",
"      Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/51\">",
"      Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Update: Guillain-Barr&eacute; syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/53\">",
"      Bradley JS, Bernstein H, Bocchini A. Allay parents' concerns over safety of 2009 H1N1 flu vaccines. AAP News 2009; 30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/54\">",
"      Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barr&eacute; syndrome. Drug Saf 2009; 32:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/55\">",
"      Glanz JM, McClure DL, Magid DJ, et al. Parental refusal of varicella vaccination and the associated risk of varicella infection in children. Arch Pediatr Adolesc Med 2010; 164:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/56\">",
"      Glanz JM, McClure DL, Magid DJ, et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics 2009; 123:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/57\">",
"      Feikin DR, Lezotte DC, Hamman RF, et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 2000; 284:3145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/58\">",
"      Salmon DA, Haber M, Gangarosa EJ, et al. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA 1999; 282:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC). Invasive Haemophilus influenzae Type B disease in five young children--Minnesota, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/60\">",
"      Hinman AR, Orenstein WA, Williamson DE, Darrington D. Childhood immunization: laws that work. J Law Med Ethics 2002; 30:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/61\">",
"      Novotny T, Jennings CE, Doran M, et al. Measles outbreaks in religious groups exempt from immunization laws. Public Health Rep 1988; 103:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/62\">",
"      Centers for Disease Control (CDC). Outbreaks of rubella among the Amish--United States, 1991. MMWR Morb Mortal Wkly Rep 1991; 40:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/63\">",
"      Fry AM, Lurie P, Gidley M, et al. Haemophilus influenzae Type b disease among Amish children in Pennsylvania: reasons for persistent disease. Pediatrics 2001; 108:E60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/64\">",
"      Centers for Disease Control and Prevention (CDC). Poliomyelitis--United States, Canada. MMWR Morb Mortal Wkly Rep 1997; 46:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/65\">",
"      Jackson BM, Payton T, Horst G, et al. An epidemiologic investigation of a rubella outbreak among the Amish of northeastern Ohio. Public Health Rep 1993; 108:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/66\">",
"      Sutter RW, Markowitz LE, Bennetch JM, et al. Measles among the Amish: a comparative study of measles severity in primary and secondary cases in households. J Infect Dis 1991; 163:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/67\">",
"      Briss PA, Fehrs LJ, Hutcheson RH, Schaffner W. Rubella among the Amish: resurgent disease in a highly susceptible community. Pediatr Infect Dis J 1992; 11:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/68\">",
"      Centers for Disease Control and Prevention (CDC). Pertussis outbreak in an Amish community--Kent County, Delaware, September 2004-February 2005. MMWR Morb Mortal Wkly Rep 2006; 55:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/69\">",
"      Filia A, De Crescenzo M, Seyler T, et al. Measles resurges in Italy: preliminary data from September 2007 to May 2008. Euro Surveill 2008; 13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/70\">",
"      Sugerman DE, Barskey AE, Delea MG, et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 2010; 125:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/71\">",
"      McBrien J, Murphy J, Gill D, et al. Measles outbreak in Dublin, 2000. Pediatr Infect Dis J 2003; 22:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/72\">",
"      Gust DA, Kennedy A, Shui I, et al. Parent attitudes toward immunizations and healthcare providers the role of information. Am J Prev Med 2005; 29:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/73\">",
"      Freed GL, Clark SJ, Butchart AT, et al. Sources and perceived credibility of vaccine-safety information for parents. Pediatrics 2011; 127 Suppl 1:S107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/74\">",
"      Diekema DS, American Academy of Pediatrics Committee on Bioethics. Responding to parental refusals of immunization of children. Pediatrics 2005; 115:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/75\">",
"      Myers MG, Orenstein WA, Marcuse EK. Countering vaccine misinformation. PREP Audio 2009; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/76\">",
"      Halperin SA. How to manage parents unsure about immunization. Canadian Journal of CME 2000; 12:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/77\">",
"      Dias M, Marcuse EK. When parents refuse immunizations. Contemp Pediatr 2000; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/78\">",
"      Kennedy A, Lavail K, Nowak G, et al. Confidence about vaccines in the United States: understanding parents' perceptions. Health Aff (Millwood) 2011; 30:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/79\">",
"      Gust DA, Kennedy A, Wolfe S, et al. Developing tailored immunization materials for concerned mothers. Health Educ Res 2008; 23:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/80\">",
"      Ball LK, Evans G, Bostrom A. Risky business: challenges in vaccine risk communication. Pediatrics 1998; 101:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/81\">",
"      Maldonado YA. Current controversies in vaccination: vaccine safety. JAMA 2002; 288:3155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/82\">",
"      Offit PA, Jew RK. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 2003; 112:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/83\">",
"      Offit PA, Hackett CJ. Addressing parents' concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics 2003; 111:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/84\">",
"      Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis 2009; 48:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/85\">",
"      Offit PA, Quarles J, Gerber MA, et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 2002; 109:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/86\">",
"      King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1994; 13:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/87\">",
"      Black SB, Cherry JD, Shinefield HR, et al. Apparent decreased risk of invasive bacterial disease after heterologous childhood immunization. Am J Dis Child 1991; 145:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/88\">",
"      Davidson M, Letson GW, Ward JI, et al. DTP immunization and susceptibility to infectious diseases. Is there a relationship? Am J Dis Child 1991; 145:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/89\">",
"      Storsaeter J, Olin P, Renemar B, et al. Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect Dis J 1988; 7:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/90\">",
"      O'Brien KL, Walters MI, Sellman J, et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 2000; 30:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/91\">",
"      Laupland KB, Davies HD, Low DE, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 2000; 105:E60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/92\">",
"      Schechter NL, Zempsky WT, Cohen LL, et al. Pain reduction during pediatric immunizations: evidence-based review and recommendations. Pediatrics 2007; 119:e1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/93\">",
"      Harrison D, Stevens B, Bueno M, et al. Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review. Arch Dis Child 2010; 95:406.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Managing injection pain. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, American Academy of Pediatrics.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/95\">",
"      Halperin B, Melnychuk R, Downie J, Macdonald N. When is it permissible to dismiss a family who refuses vaccines? Legal, ethical and public health perspectives. Paediatr Child Health 2007; 12:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/96\">",
"      Flanagan-Klygis EA, Sharp L, Frader JE. Dismissing the family who refuses vaccines: a study of pediatrician attitudes. Arch Pediatr Adolesc Med 2005; 159:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/97\">",
"      Leib S, Liberatos P, Edwards K. Pediatricians' experience with and response to parental vaccine safety concerns and vaccine refusals: a survey of Connecticut pediatricians. Public Health Rep 2011; 126 Suppl 2:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/98\">",
"      Salmon DA, Omer SB. Individual freedoms versus collective responsibility: immunization decision-making in the face of occasionally competing values. Emerg Themes Epidemiol 2006; 3:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/99\">",
"      Ross LF, Aspinwall TJ. Religious exemptions to the immunization statutes: balancing public health and religious freedom. J Law Med Ethics 1997; 25:202.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine.The childhood immunization schedule and safety:",
"Stakeholder concerns, scientific evidence, and future studies. The National Academies Press, Washington, D.C. 2013. file://www.nap.edu/catalog.php?record_id=13563 (Accessed on January 21, 2013).",
"    </li>",
"    <li>",
"     Sears RW. The Vaccine Book: Making the Right Decision for Your Child, Little, Brown and Company, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/102\">",
"      Offit PA, Moser CA. The problem with Dr Bob's alternative vaccine schedule. Pediatrics 2009; 123:e164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/103\">",
"      Smith MJ, Woods CR. On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes. Pediatrics 2010; 125:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/104\">",
"      Kimberlin DW, Bocchini JA. Monovalent vaccines no longer available for measles, mumps, rubella. AAP News 2009; 30:9.",
"     </a>",
"    </li>",
"    <li>",
"     If you chooose not to vaccinate your child, understand the risks and resonsibilities. www.cdc.gov/vaccines/spec-grps/hcp/conv-materials.htm#providers (Accessed on February 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/106\">",
"      Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 1999; 17 Suppl 3:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/61/19418/abstract/107\">",
"      Parikh RK. Fighting for the reputation of vaccines: lessons from American politics. Pediatrics 2008; 121:621.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2846 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19418=[""].join("\n");
var outline_f18_61_19418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STATE LAWS REGARDING VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Demographics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vaccine beliefs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      WHY PARENTS REFUSE VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General objections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Specific objections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - MMR vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HPV vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Meningococcal conjugate vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Thimerosal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CONSEQUENCES OF VACCINE REFUSAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      For the individual",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      For the community",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overview of approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Establish dialogue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Identify concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Target education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Vaccine limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Misconceptions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Maintain relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Alternative schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Special precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2846|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/25/10645\" title=\"figure 1\">",
"      Vaccine effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/9/32926\" title=\"figure 2\">",
"      Measles vaccine exemptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/55/25463\" title=\"figure 3A\">",
"      Childhood immunization schedule 0 to 6 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/56/27523\" title=\"figure 3B\">",
"      Childhood immunization schedule 7 to 18 yrs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2846|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/56/14223\" title=\"table 1\">",
"      Immunization resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_61_19419="Dosing of antiviral medications for genital HSV";
var content_f18_61_19419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of antiviral medications for adults with genital herpes simplex virus infection in persons with HIV",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acyclovir*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Valacyclovir",
"       </td>",
"       <td class=\"subtitle1\">",
"        Famciclovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First episode or recurrence",
"       </td>",
"       <td>",
"        400 mg&nbsp;orally three times daily&nbsp;for 5 to 10 days&bull;",
"       </td>",
"       <td>",
"        1 gram&nbsp;orally twice daily&nbsp;for 5 to10 days&bull;",
"       </td>",
"       <td>",
"        <p>",
"         500 mg&nbsp;orally twice daily&nbsp;for 5 to10 days&bull;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suppression",
"       </td>",
"       <td>",
"        400 to 800 mg orally&nbsp;twice daily or three times daily",
"       </td>",
"       <td>",
"        500 mg orally twice daily",
"       </td>",
"       <td>",
"        500 mg orally&nbsp;twice daily",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    HIV: human immunodeficiency virus; HSV: herpes simplex virus",
"    <div class=\"footnotes\">",
"     * Intravenous (IV) acyclovir therapy should be provided for patients who have severe HSV disease or complications that necessitate hospitalization.",
"     <br>",
"      &bull; &nbsp;Length of therapy dependent upon resolution of lesions. Therapy should be continued for longer than 10 days if lesions persist.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):23-4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19419=[""].join("\n");
var outline_f18_61_19419=null;
var title_f18_61_19420="Brachytherapy esophagus CA selection criteria";
var content_f18_61_19420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selection criteria for definitive and palliative brachytherapy for esophageal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Definitive treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Good candidates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Unifocal thoracic esophageal cancer &le;10 cm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            No extraesophageal extension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            No nodal disease or metastatic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Poor candidates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tumor &gt;10 cm in length",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Extraesophageal extension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Regional lymphadenopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tumor involving GE junction or cardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Contraindications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Esophageal fistula",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cervical esophageal location",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Stenosis that cannot be bypassed",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Palliative treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thoracic esophageal lesions with distant metastases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Unresectable local disease progression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Recurrence after definitive EBRT",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GE: gastroesophageal; EBRT: external beam radiation therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Gaspar LE, Nag S, Herskovic A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys 1997; 38:127.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19420=[""].join("\n");
var outline_f18_61_19420=null;
var title_f18_61_19421="Food-borne diseases VI";
var content_f18_61_19421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for confirmation of food-borne disease outbreaks-VI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiologic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chemical (cont.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"4\">",
"        Mushroom toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Shorter-acting toxins:",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"6\">",
"        &le;2 hrs",
"       </td>",
"       <td class=\"sublist_other\">",
"        Usually vomiting and diarrhea, other symptoms differ with toxin:",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"6\">",
"        <p>",
"         Clinical syndrome among persons who have eaten mushroom identified as toxic type",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Demonstration of toxin in epidemiologically implicated mushroom or mushroom-containing food",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Muscimol",
"       </td>",
"       <td class=\"sublist_other\">",
"        Confusion, visual disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Muscarine",
"       </td>",
"       <td class=\"sublist_other\">",
"        Salivation, diaphoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Psilocybin",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hallucinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        <em>",
"         Coprinus artrementarius",
"        </em>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Disulfiram-like reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Ibotenic acid",
"       </td>",
"       <td class=\"sublist_other\">",
"        Confusion, visual disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" rowspan=\"3\">",
"        Longer-acting toxin (eg,",
"        <em>",
"         Amanita",
"        </em>",
"        spp.)",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        6-24 hrs",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        Diarrhea and abdominal cramps for 24 hrs followed by hepatic and renal failure",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clinical syndrome among persons who have eaten mushroom identified as toxic type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Demonstration of toxin in epidemiologically implicated mushroom or mushroom-containing food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Cryptosporidium parvum",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        2-28 days, median: 7 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, nausea, vomiting, fever",
"       </td>",
"       <td>",
"        Demonstration of organism or antigen in stool or in small-bowel biopsy of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of organism in epidemiologically implicated food",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        <em>",
"         Cyclospora cayetanensis",
"        </em>",
"       </td>",
"       <td>",
"        1-11 days, median: 7 days",
"       </td>",
"       <td>",
"        Fatigue, protracted diarrhea, often relapsing",
"       </td>",
"       <td>",
"        Demonstration of organism in stool of two or more ill persons",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Giardia lamblia",
"        </em>",
"       </td>",
"       <td rowspan=\"3\">",
"        3-25 days, median: 7 days",
"       </td>",
"       <td rowspan=\"3\">",
"        Diarrhea, gas, cramps, nausea, fatigue",
"       </td>",
"       <td>",
"        Two or more ill persons and detection of antigen in stool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of organism in stool, duodenal contents, or small-bowel biopsy specimen",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Trichinella",
"        </em>",
"        spp.",
"       </td>",
"       <td rowspan=\"3\">",
"        1-2 days for intestinal phase; 2-4 wks for systemic phase",
"       </td>",
"       <td rowspan=\"3\">",
"        Fever, myalgia, periorbital edema, high eosinophil count",
"       </td>",
"       <td>",
"        Two or more ill persons and positive serologic test or demonstration of larvae in muscle biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstration of larvae in epidemiologically implicated meat",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.cdc.gov/mmwr//mmwr.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19421=[""].join("\n");
var outline_f18_61_19421=null;
var title_f18_61_19422="Back pain clinical features";
var content_f18_61_19422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and radiographic features of selected causes of back pain in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Musculoskeletal causes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical age group/risk groups",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features on plain films",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spondylolysis",
"       </td>",
"       <td>",
"        <p>",
"         Early adolescence",
"        </p>",
"        <p>",
"         Inuit &gt; whites &gt; blacks",
"        </p>",
"        <p>",
"         Boys &gt; girls",
"        </p>",
"        <p>",
"         Associated with Scheuermann kyphosis",
"        </p>",
"        <p>",
"         Associated with gymnastics, dance/ballet, diving, weight lifting, figure skating, volleyball, soccer, football (linemen), racquet sports, throwing sports",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lumbosacral pain (usually L5)",
"        </p>",
"        <p>",
"         Pain with extension",
"        </p>",
"        <p>",
"         Hamstring tightness",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lateral view: healing defect of pars interarticularis",
"        </p>",
"        <p>",
"         Oblique views: \"Scotty dog sign\"*",
"        </p>",
"        <p>",
"         (SPECT scan is most sensitive)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spondylolisthesis",
"       </td>",
"       <td>",
"        As for spondylolysis",
"       </td>",
"       <td>",
"        <p>",
"         Lumbosacral pain (usually L5)",
"        </p>",
"        <p>",
"         Pain with extension",
"        </p>",
"        <p>",
"         Hamstring tightness",
"        </p>",
"        <p>",
"         Prominent spinous process",
"        </p>",
"        <p>",
"         Flattening of normal lumbar lordosis",
"        </p>",
"        <p>",
"         Knee-flexed, hip-flexed gait (Phalen-Dickson sign)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lateral view: anterior slippage of vertebral body",
"        </p>",
"        <p>",
"         Oblique view: lucent collar",
"        </p>",
"        <p>",
"         Stepladder sign*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic scoliosis",
"       </td>",
"       <td>",
"        Adolescents",
"       </td>",
"       <td>",
"        Lateral spinal curvature",
"       </td>",
"       <td>",
"        <p>",
"         Full length (C7 to the sacrum/iliac crest)",
"        </p>",
"        <p>",
"         PA view: lateral curvature",
"        </p>",
"        <p>",
"         Lateral view: spinal curvature in sagittal plane",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scheuermann (juvenile) kyphosis",
"       </td>",
"       <td>",
"        <p>",
"         Early adolescence",
"        </p>",
"        <p>",
"         Boys &gt; girls",
"        </p>",
"        <p>",
"         Tall boys",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Subacute/chronic thoracic or thoracolumbar pain",
"        </p>",
"        <p>",
"         Increased pain with flexion",
"        </p>",
"        <p>",
"         Rigid thoracic kyphosis",
"        </p>",
"        <p>",
"         Increased lumbar lordosis",
"        </p>",
"        <p>",
"         Hamstring tightening",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lateral view: anterior wedging of &ge;5&deg; in &ge;3 adjacent vertebral bodies",
"        </p>",
"        <p>",
"         Degeneration of vertebral end-plates",
"        </p>",
"        <p>",
"         Herniation of intervertebral disc material into vertebral body end-plate (Schmorl node)",
"        </p>",
"        <p>",
"         May be associated with spondylolysis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervertebral disc herniation",
"       </td>",
"       <td>",
"        <p>",
"         Adolescents",
"        </p>",
"        <p>",
"         Acute trauma",
"        </p>",
"        <p>",
"         Scheuermann kyphosis",
"        </p>",
"        <p>",
"         Family history of intervertebral disc herniation",
"        </p>",
"        <p>",
"         Associated with weight lifting, wrestling, gymnastics, collision sports",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Lumbar pain",
"        </p>",
"        <p>",
"         Sciatica",
"        </p>",
"        <p>",
"         Limited spinal flexibility",
"        </p>",
"        <p>",
"         Limited passive straight-leg raising",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Usually normal",
"        </p>",
"        <p>",
"         May show slight posterior calcification",
"        </p>",
"        <p>",
"         (MRI is preferred imaging modality)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intervertebral disc calcification",
"       </td>",
"       <td>",
"        <p>",
"         Preadolescents",
"        </p>",
"        <p>",
"         Ochronosis&bull;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Generally affects cervical and/or thoracic discs",
"        </p>",
"        <p>",
"         Torticollis",
"        </p>",
"       </td>",
"       <td>",
"        Intervertebral disc calcification",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Infectious causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discitis",
"       </td>",
"       <td>",
"        0 to 5 years",
"       </td>",
"       <td>",
"        <p>",
"         Generally affects lower lumbar spine",
"        </p>",
"        <p>",
"         Gradual onset of back pain or irritability, refusal to crawl or walk",
"        </p>",
"        <p>",
"         Minimal systemic toxicity",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Narrowing of intervertebral joint space after two to three weeks of symptoms, followed by destruction of vertebral end-plates and disc herniation",
"        </p>",
"        <p>",
"         Diagnosis is best made by MRI",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vertebral osteomyelitis",
"       </td>",
"       <td>",
"        Adolescents",
"       </td>",
"       <td>",
"        <p>",
"         Fever",
"        </p>",
"        <p>",
"         Ill appearance",
"        </p>",
"       </td>",
"       <td>",
"        Destructive changes of vertebral bodies (after two to three weeks of symptoms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sacroiliac joint infection",
"       </td>",
"       <td>",
"        Late childhood",
"       </td>",
"       <td>",
"        <p>",
"         Pain over sacrum",
"        </p>",
"        <p>",
"         Fever",
"        </p>",
"        <p>",
"         Pain with maneuvers that twist the pelvis (eg, the FABERE test)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         May demonstrate sclerosis of the sacroiliac joint",
"        </p>",
"        <p>",
"         Widening of the joint space",
"        </p>",
"        <p>",
"         Blurring of subchondral plate",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epidural abscess",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Fever",
"        </p>",
"        <p>",
"         Spinal pain",
"        </p>",
"        <p>",
"         Neurologic deficit",
"        </p>",
"       </td>",
"       <td>",
"        MRI is preferred imaging modality",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Inflammatory arthritis",
"        </strong>",
"       </td>",
"       <td>",
"        Family history of inflammatory spondylitis",
"       </td>",
"       <td>",
"        <p>",
"         Chronic pain",
"        </p>",
"        <p>",
"         Morning stiffness",
"        </p>",
"        <p>",
"         Sacroiliac joint tenderness (eg, positive FABERE test)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erosion or sclerosis at anterior vertebral corners",
"        </p>",
"        <p>",
"         Vertebral squaring",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteoid osteoma",
"       </td>",
"       <td>",
"        Second decade of life",
"       </td>",
"       <td>",
"        <p>",
"         Nocturnal pain",
"        </p>",
"        <p>",
"         Prompt relief with NSAIDs",
"        </p>",
"        <p>",
"         May be associated with scoliosis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Osteoid nidus with or without calcification (osteoid nidus may be obscured by dense sclerosis)",
"        </p>",
"        <p>",
"         Sclerosis of posterior elements",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant tumors (eg, leukemia, lymphoma, Ewing sarcoma, etc.)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Nighttime pain",
"        </p>",
"        <p>",
"         Constant pain (unchanged by activity)",
"        </p>",
"        <p>",
"         Pain &lt;3 months duration",
"        </p>",
"        <p>",
"         Systemic symptoms (eg, fever, weight loss)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bony destruction",
"        </p>",
"        <p>",
"         Subtle signs of space-occupying lesion (separation or thinning of the pedicles)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SPECT scan: single photon emission computed tomography scan; MRI: magnetic resonance imaging; PA: posteroanterior; FABERE:",
"     <strong>",
"      F",
"     </strong>",
"     lexion of the hip and knee,",
"     <strong>",
"      AB",
"     </strong>",
"     duction and",
"     <strong>",
"      E",
"     </strong>",
"     xternal",
"     <strong>",
"      R",
"     </strong>",
"     otation of the hip,",
"     <strong>",
"      E",
"     </strong>",
"     xtension of the opposite hip (also called the figure-of-four test) (see text for details); NSAIDS: nonsteroidal antiinflammatory drugs.",
"     <br>",
"      * See text for details.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Ochronosis: exogenously deposited or medication-induced pigmentation of the connective tissue.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19422=[""].join("\n");
var outline_f18_61_19422=null;
var title_f18_61_19423="Central calcification on CT II";
var content_f18_61_19423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary nodule with central calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right middle lobe nodule with characteristic target calcification diagnostic for a benign granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_61_19423=[""].join("\n");
var outline_f18_61_19423=null;
